Ion channel expression in human melanoma samples. in silico identification and experimental validation of molecular targets by D’Arcangelo, Daniela et al.
cancers
Article
Ion Channel Expression in Human Melanoma
Samples: In Silico Identification and Experimental
Validation of Molecular Targets
Daniela D’Arcangelo 1, Francesca Scatozza 1, Claudia Giampietri 2 , Paolo Marchetti 3,
Francesco Facchiano 4 and Antonio Facchiano 1,*
1 Istituto Dermopatico dell’Immacolata (IDI-IRCCS), 00167 Rome, Italy; d.darcangelo@idi.it (D.D.);
f.scatozza@idi.it (F.S.)
2 Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Unit of Histology and Medical
Embryology, Sapienza University of Rome, 00161 Rome, Italy; claudia.giampietri@uniroma1.it
3 Medical Oncology, Sapienza, University of Rome, 00161 Rome, Italy; paolo.marchetti@uniroma1.it
4 Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità (ISS), 00161 Rome, Italy;
francesco.facchiano@iss.it
* Correspondence: a.facchiano@idi.it
Received: 5 March 2019; Accepted: 23 March 2019; Published: 29 March 2019


Abstract: Expression of 328 ion channel genes was investigated, by in silico analysis, in 170 human
melanoma samples and controls. Ninety-one members of this gene-family (i.e., about 28%) show
a significant (p < 0.05) differential expression in melanoma- vs. nevi-biopsies, taken from the GEO
database. ROC (receiver operating characteristic) analysis selected 20 genes as potential markers
showing the highest discrimination ability of melanoma vs. nevi (AUC > 0.90 and p < 0.0001). These
20 genes underwent a first in silico-validation round in an independent patients-dataset from GEO.
A second-in silico-validation step was then carried out on a third human dataset in Oncomine.
Finally, five genes were validated, showing extremely high sensitivity and specificity in melanoma
detection (>90% in most cases). Such five genes (namely, SCNN1A, GJB3, KCNK7, GJB1, KCNN2)
are novel potential melanoma markers or molecular targets, never previously related to melanoma.
The “druggable genome” analysis was then carried out. Miconazole, an antifungal drug commonly
used in clinics, is known to target KCNN2, the best candidate among the five identified genes.
Miconazole was then tested in vitro in proliferation assays; it dose-dependently inhibited proliferation
up to 90% and potently induced cell-death in A-375 and SKMEL-28 melanoma cells, while it showed
no effect in control cells. Moreover, specific silencing of KCNN2 ion channel was achieved by
siRNA transfection; under such condition miconazole strongly increases its anti-proliferative effect.
In conclusion, the present study identified five ion channels that can potentially serve as sensitive
and specific markers in human melanoma specimens and demonstrates that the antifungal drug
miconazole, known to target one of the five identified ion channels, exerts strong and specific
anti-melanoma effects in vitro.
Keywords: KCNN2; ion channels; melanoma; miconazole
1. Introduction
Ion channels play a key role in the physiology of any cell- and tissue-type; this makes ion channels
ideal potential therapeutic targets [1]. In a way, they represent the tollbooths filtering the molecular flux
on the highways connecting the intracellular to the extracellular environment. Given the exceptional
role of ion channels in controlling almost any cellular function, drugs targeting ion channels may cover
a market of several billion USD [2]. Thus, it is no surprise the large interest pharmaceutical companies
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give to ion channels as molecular targets in many different pathological conditions, such as pain
relief [3], cardiovascular diseases [4–6], diabetes [7], infectious diseases such as Hepatitis C virus [8]
and influenza virus [9], CNS diseases [10–13], and cystic fibrosis [14,15]. Increasing interest is currently
given to ion channels in cancers since they have been indicated as potential drug targets in many
cancer conditions [16–18]. We have recently reported an extensive ion channels expression analysis in
several solid tumors demonstrating relevant and significant alterations in bladder cancer, glioblastoma,
melanoma, breast cancer, and lung carcinoma, in more than 3000 patients [19], further indicating ion
channels as potential therapeutic targets or molecular markers in cancer field. Indeed, ion channels
expression has been related to clinical outcome in breast cancer [20] and the role of different ion
channels has been recently demonstrated in lung cancer [21,22] as well as prostate cancer [23–25].
Mutation in glutamate receptors have been related to increased survival in malignant melanoma [26].
In addition, directly targeting mitochondrial potassium channels exerts a potent antitumor effect
in vivo in melanoma and in pancreatic adenocarcinoma mouse models [27]. These data confirm the
crucial role ion channels play in many cancer conditions including melanoma and prompted us to
investigate the expression level of 328 ion channels in human melanoma samples looking for ion
channels genes acting as potential markers and molecular targets in a melanoma set up.
2. Results
The general procedure followed in the present study is summarized in Figure 1.
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2.1. Selection Phase
The expression level of each of the 328 genes reported in Table 1 was compared in melanoma vs.
controls. Table 2 reports the 91 genes showing a statistically different expression level in melanoma vs.
controls (p < 0.05). The genes are reported in order of their p value, starting from the most significant
(p > 10−18) down to the p > 0.05 threshold. Indeed, more than half of such genes fall within the p value
below the 10−4 range, highlighting that a relevant number of members of the ion channels family are
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strongly and significantly modified in melanoma biopsies. For each gene, the computed fold change
in melanoma vs. controls is also indicated, along with the AUC (area under the curve) according
to the ROC (receiver operating characteristic) analysis. AUC indicates the ability to discriminate
melanoma from nevi samples. Several genes show an extremely significant p value combined with a
high fold change and high AUC value. Genes showing AUC > 0.90 and a p < 0.0001, i.e., a significant
discriminating ability of at least 90%, were selected and are reported in Table 3, sorted according to the
AUC level.
The analysis was carried out in GDS1375 dataset from the GEO database, containing data from 45
melanoma biopsies and 18 normal skin biopsies.
2.1.1. First-Round Validation Step
The 20 genes having AUC ≥ 0.90 according to the expression levels reported in the GEO dataset
GDS1375 were then analyzed in a different human samples dataset (GEO GSE15605) presenting data
from 62 patients. Eleven genes showing an AUC level ≥ 0.85 in the second dataset were selected as
genes validated in the 1st round validation, namely: SCNN1A, ANO1, GJA1, GJB3, SCNN1B, GABRE,
KCNK7, KCND3, KCNK1, GJB1, KCNN2 (see Table 3).
2.1.2. Second-Round Validation Step
The 11 genes analyzed in GDS1375 and first-round validated in GSE15605 were then analyzed
in a third dataset, namely the Riker dataset from Oncomine database. The seven genes showing an
expression ratio in melanoma/controls <0.5 or >2 were then identified, namely: SCNN1A, ANO1, GJB3,
GABRE, KCNK7, GJB1, KCNN2 (see Table 3) and were considered second-round validated. Any known
relation of these five genes with melanoma was then investigated according to a PubMed search, and
they were all selected as novel genes:
SCNN1A (“Sodium Channel Epithelial 1 Alpha Subunit”, sodium channel, non-voltage-gated,
amiloride sensitive),
GJB3 (“Gap Junction Protein Beta 3”, gap-junction component, connexin gene family member),
KCNK7 (“Potassium Two Pore Domain Channel Subfamily K Member 7”, potassium channel),
GJB1 (“Gap Junction Protein Beta 1”, gap-junction component, connexin gene family member),
KCNN2 (“Potassium Calcium-Activated Channel Subfamily N Member 2”, potassium channel).
No co-occurrence of their gene name or synonymous names is reported with “melanoma” word,
in any field in PubMed searches (see Table 3, right end-side column). These five genes were then
selected as the best novel candidates as melanoma markers and melanoma molecular targets. Figure 2
depicts the corresponding ROC curves of the five best candidates computed on the expression values
reported in the GDS 1375 dataset. In all cases an AUC > 0.90 and p < 0.0001 is reported, i.e., a very
high and significant ability to discriminate melanoma from healthy controls samples. The sensitivity
and specificity values were computed as reported in the Methods section, indicating: 92% specificity
and 97.7% sensitivity for SCNN1A; 96% specificity and 91% sensitivity for GJB3; 84% specificity and
97.7 sensitivity for KCNK7; 96% specificity and 84.4% sensitivity for GJB1; 100% specificity and 82.2%
sensitivity for KCNN2.
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Table 1. Ion channels genes investigated in the present study, selected according to HUGO Gene Nomenclature Committee at https://www.genenames.org/cgi-bin/
genefamilies/.
No. Gene Name No. Gene Name No. Gene Name No. Gene Name No. Gene Name No. Gene Name
1 ANO1 56 CACNG5 111 GABRB1 166 GRIN2D 221 KCNJ2 276 P2RX6
2 ANO10 57 CACNG6 112 GABRB2 167 GRIN3A 222 KCNJ3 277 P2RX7
3 ANO2 58 CACNG7 113 GABRB3 168 GRIN3B 223 KCNJ4 278 PKD2
4 ANO3 59 CACNG8 114 GABRD 169 HCN1 224 KCNJ5 279 PKD2L1
5 ANO4 60 CATSPER1 115 GABRE 170 HCN2 225 KCNJ6 280 PKD2L2
6 ANO5 61 CATSPER2 116 GABRG1 171 HCN3 226 KCNJ8 281 RYR1
7 ANO6 62 CATSPER3 117 GABRG2 172 HCN4 227 KCNJ9 282 RYR2
8 ANO7 63 CATSPER4 118 GABRG3 173 HTR3A 228 KCNK1 283 RYR3
9 ANO8 64 CATSPERB 119 GABRP 174 HTR3B 229 KCNK10 284 SCN10A
10 ANO9 65 CATSPERD 120 GABRQ 175 HTR3C 230 KCNK12 285 SCN11A
11 AQP1 66 CATSPERG 121 GABRR1 176 HTR3D 231 KCNK13 286 SCN1A
12 AQP10 67 CFTR 122 GABRR2 177 HTR3E 232 KCNK15 287 SCN1B
13 AQP11 68 CHRNA1 123 GABRR3 178 HVCN1 233 KCNK16 288 SCN2A
14 AQP12A 69 CHRNA10 124 GJA1 179 ITPR1 234 KCNK17 289 SCN2B
15 AQP12B 70 CHRNA2 125 GJA10 180 ITPR2 235 KCNK18 290 SCN3A
16 AQP2 71 CHRNA3 126 GJA3 181 ITPR3 236 KCNK2 291 SCN3B
17 AQP3 72 CHRNA4 127 GJA4 182 KCNA1 237 KCNK3 292 SCN4A
18 AQP4 73 CHRNA5 128 GJA5 183 KCNA10 238 KCNK4 293 SCN4B
19 AQP5 74 CHRNA6 129 GJA6P 184 KCNA2 239 KCNK5 294 SCN5A
20 AQP6 75 CHRNA7 130 GJA8 185 KCNA3 240 KCNK6 295 SCN8A
21 AQP7 76 CHRNA9 131 GJA9 186 KCNA4 241 KCNK7 296 SCN9A
22 AQP8 77 CHRNB1 132 GJB1 187 KCNA5 242 KCNK9 297 SCNN1A
23 AQP9 78 CHRNB2 133 GJB2 188 KCNA6 243 KCNMA1 298 SCNN1B
24 ASIC1 79 CHRNB3 134 GJB3 189 KCNA7 244 KCNN1 299 SCNN1D
25 ASIC2 80 CHRNB4 135 GJB4 190 KCNB1 245 KCNN2 300 SCNN1G
26 ASIC3 81 CHRND 136 GJB5 191 KCNB2 246 KCNN3 301 TPCN1
27 ASIC4 82 CHRNE 137 GJB6 192 KCNC1 247 KCNN4 302 TPCN2
28 ASIC5 83 CHRNG 138 GJB7 193 KCNC2 248 KCNQ1 303 TRPA1
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Table 1. Cont.
No. Gene Name No. Gene Name No. Gene Name No. Gene Name No. Gene Name No. Gene Name
29 BEST1 84 CLCN1 139 GJC1 194 KCNC3 249 KCNQ2 304 TRPC1
30 BEST2 85 CLCN2 140 GJC2 195 KCNC4 250 KCNQ3 305 TRPC2
31 BEST3 86 CLCN3 141 GJC3 196 KCND1 251 KCNQ4 306 TRPC3
32 BEST4 87 CLCN4 142 GJD2 197 KCND2 252 KCNQ5 307 TRPC4
33 BSND 88 CLCN5 143 GJD3 198 KCND3 253 KCNS1 308 TRPC5
34 CACNA1A 89 CLCN6 144 GJD4 199 KCNF1 254 KCNS2 309 TRPC6
35 CACNA1B 90 CLCN7 145 GJE1 200 KCNG1 255 KCNS3 310 TRPC7
36 CACNA1C 91 CLCNKA 146 GLRA1 201 KCNG2 256 KCNT1 311 TRPM1
37 CACNA1D 92 CLCNKB 147 GLRA2 202 KCNG3 257 KCNT2 312 TRPM2
38 CACNA1E 93 CLIC1 148 GLRA3 203 KCNG4 258 KCNU1 313 TRPM3
39 CACNA1F 94 CLIC2 149 GLRA4 204 KCNH1 259 KCNV1 314 TRPM4
40 CACNA1G 95 CLIC3 150 GLRB 205 KCNH2 260 KCNV2 315 TRPM5
41 CACNA1H 96 CLIC4 151 GRIA1 206 KCNH3 261 LRRC8A 316 TRPM6
42 CACNA1I 97 CLIC5 152 GRIA2 207 KCNH4 262 LRRC8B 317 TRPM7
43 CACNA1S 98 CLIC6 153 GRIA3 208 KCNH5 263 LRRC8C 318 TRPM8
44 CACNA2D1 99 CNGA1 154 GRIA4 209 KCNH6 264 LRRC8D 319 TRPV1
45 CACNA2D2 100 CNGA2 155 GRID1 210 KCNH7 265 LRRC8E 320 TRPV2
46 CACNA2D3 101 CNGA3 156 GRID2 211 KCNH8 266 MCOLN1 321 TRPV3
47 CACNA2D4 102 CNGA4 157 GRIK1 212 KCNJ1 267 MCOLN2 322 TRPV4
48 CACNB1 103 CNGB1 158 GRIK2 213 KCNJ10 268 MCOLN3 323 TRPV5
49 CACNB2 104 CNGB3 159 GRIK3 214 KCNJ11 269 MIP 324 TRPV6
50 CACNB3 105 GABRA1 160 GRIK4 215 KCNJ12 270 NALCN 325 VDAC1
51 CACNB4 106 GABRA2 161 GRIK5 216 KCNJ13 271 P2RX1 326 VDAC2
52 CACNG1 107 GABRA3 162 GRIN1 217 KCNJ14 272 P2RX2 327 VDAC3
53 CACNG2 108 GABRA4 163 GRIN2A 218 KCNJ15 273 P2RX3 328 ZACN
54 CACNG3 109 GABRA5 164 GRIN2B 219 KCNJ16 274 P2RX4
55 CACNG4 110 GABRA6 165 GRIN2C 220 KCNJ18 275 P2RX5
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in
the GEO GDS1375 dataset.
No. GeneName
t Test Nevi vs.
Melanoma
Ratio Melanoma
vs. Nevi AUC No. Gene Name




1 ANO1 8.7 × 10−18 0.231
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1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.98 47 ACNB2 1.5 × 10−3 0.4388
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25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.94 48 TRPV6 1.9 × 10−3 0.576
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 S NN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.  × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.65
3 SCNN1A 1.0 × 10−14 0.07
Cancers 2019, 11, x 6 of 22 
Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.98 49 CLIC2 2. × 10−3 0.319
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 S NN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.  × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.87
4 SCNN1B 1.4 × 10−14 0.313
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 1 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLI 2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACN 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPE 2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.96 50 SCN3A 2.2 × 10−3 0.382
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 A O1 8 7 8 31 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLIC2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACNA11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.   −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPER2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.64
5 GABRE 2.3 × 10−13 0.203
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 1 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLI 2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACN 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPE 2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.95 51 GRIN2A 2.3 × 10−3 0.619
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 31 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLIC2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACNA11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.   −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPER2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
6 GJB5 3.4 × 10−13 0.1277
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 31 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLI 2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACN 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPE 2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.97 52 ACNG4 2.6 × 10−3 1.317
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.21   0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B .6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
.74
7 CLIC1 1.9 × 10−12 1.738
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 8  KCNA1 3.0 × 0−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 0−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 0−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB  3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 0−2 1.3   0.72 
41 MCO 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 0−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 0−2 0.71  0.63 
43 LRR 8D 2.  × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 0−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.95 53 GABRB 3. × 10−3 0.698
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLIC2 2 3 9 87
4 S NN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.   −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
8 KCND3 2.0 × 10−11 0.487
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLI 2 2 3 9 87
4 SCNN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CN 11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.1  −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPE 2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.94 54 GJ 4 3.7 × 10−3 0.588
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLIC2 2 3 9 87
4 S NN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.   −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
9 KCNK1 8.6 × 10−11 0.269
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.1  −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.93 55 AC B4 4.3 × 10−3 0.474
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN1A 1 4 0.07 8 49 CLIC2 2 3 9 87
4 S NN1B 1 4 4 0.313 0 SCN3A 2 2 382 64
5 GABRE 2 3 − 3 0 203 5 1 GRIN2A 2 3 0 619 69
6 JB5 3 4 3 0.1277 97 52 CACNG4 2 6 317 4
7 CLIC1 .9  −12 1 738 5 53 ABRB1 3 0 0 698 69
8 KCND3 2.0  −11 0.487 94 54 GJB4 3 7 588 3
9 KCNK1 8.6  −11 269 3 55 CACNB4 4 3 0.474 66
0 GRIA1 8.7  −11 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 96 57 KCNK2 5 0 0.512 4
12 3 2.   −10 0.2453 6 58 TRPC1 5 4 0.665 70
13 KCNN2 3.6  -10 4 337 91 59 TRPC7 5 7 1 39 7
14 AQP1 5.5  −10 268 84 0 GRIK1 6 3 3 1.885 72
15 ITPR3 1 9 2.311 93 1 GRI 2  6 7 3 1 922 75
16 YR1 1 8 9 0.2414 81 62 CL C  6 8 3 0.671 9
17 GJA1 2 1 9 08 98 63 CACNA1S 7 7 3 1.91 7
18 KCNJ13 1 8 2 6 86 64 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.66
10 GRIA1 8.7 × 10−11 0.1049
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388  . 3 
2 KCNK7 1.8  7 .081  .  48 T PV6 1.9   .576  .65 
3 SCNN1A 4 0.07  . 8 49 CLI 2 2.    .3 9  .87 
4 SCNN B 4 4 0.313  .  0 SCN3A 2.2   .382  . 4 
5 GABRE 3 − 3 .203  . 5 1 GRI 2A 2.3   0 619  .69 
6 GJB5 3 4 3 0.1277  .97 52 CACNG4 2.6   .31   . 4 
7 CLIC1 .9  −12 1 738  . 5 53 BRB1 3.0   0 698  .  
8 KCND3 2.0  −11 0.487  . 4 54 B  3.7   588  . 3 
9 KCNK1 8.6  −11 .269  . 3 55 CACNB4 4.3   .474  . 6 
0 G IA1 8.7  −11 0.1049  . 3 56 CN 11 5.    29  . 0 
1 VDAC1 .   −10 1.8  .96 57 KCNK2 5.    .512  . 4 
12 3 2.1  −10 0.2453  . 6 58 T PC1 5.4  −  0.665  .70 
13 KCNN2 .   -10 4.337  .91 59 7 5.7   1.39   .  
14 1 5.5  −10 .2 8  .84 0 G IK1 6.3  3 1.885  .72 
15 ITPR3 .   −9 2.311  .  1 GRI 2  6.7  −3 1 922  .  
16 YR1 .8  9 0.2414  . 1 62 CL C  6.8  3 0.671  . 9 
17 GJA1 2.1  9 .08   .98 63 CA A S 7.7  3 1.91  . 7 
18 KCNJ13 1.   8 .2 6  . 6 64 ATSPE 2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.93 56 A A 1 5. × 10−3 0.6 9
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388  . 3 
2 CNK7 1.8  7 .081  .  48 T PV6 1.9   .576  .65 
3 S NN A 4 0.07  . 8 49 CLIC2 2.    .3 9  .87 
4 S NN B 4 4 313  .  0 SCN3A 2.2   .3 2  . 4 
5 G BRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 JB5 3 4 3 277  . 7 2 CAC G4 2.6   .31   . 4 
7 CLIC1 9 2 1 738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CNA11 5.    29  . 0 
1 VDAC1 .   −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 3 2.   −10 53  . 6 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.39   .  
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .   −9 2.311  .  1 RI 2  6.7  −  1 922  .  
16 YR1 .8  9 0.2414  . 1 2 CL C  6.8   0.671  . 9 
17 GJA1 2.1  9 .08  .98 3 CA A S 7.7   1.91  . 7 
18 K NJ13 1.    .2 6  . 6 4 ATSPER2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.70
11 VDAC1 2.0 × 10−10 1.8
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.  × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 0−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 0-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 8  K NA1 3.0 × 0−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 0−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB  3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 0−2 1.3   0.72 
41 MCO 3 2.  × 10−4 0.352  0.62 87 TRPV5 4.0 × 0−2 1.29  0.66 
42 SCN2  2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 0−2 0.71  0.63 
43 LRR 8  2.  × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN  3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.96 57 2 5. × 10−3 0.512
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388  . 3 
2 CNK7 .8  7 .081  .  48 T PV6 1.9   .576  .65 
3 S NN A 4 0.07  . 8 49 CLIC2 2.    .3 9  .87 
4 S NN B 4 4 313  .  0 SCN3A 2.2   .3 2  . 4 
5 G BRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 GJB5 3 4 3 277  . 7 2 CAC G4 2.6   .31   . 4 
7 CLIC1 9 2 1 738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CNA11 5.    29  . 0 
1 VDAC1 .   −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 3 2.   −10 53  . 6 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.39   .  
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .   −9 2.311  .  1 RI 2  6.7  −  1 922  .  
16 YR1 .8  9 0.2414  . 1 2 CL C  6.8   0.671  . 9 
17 GJA1 2.1  9 .08   .98 3 CA A S 7.7   1.91  . 7 
18 K NJ13 1.    .2 6  . 6 4 ATSPER2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.64
12 GJB3 2.1 × 10−10 0.245
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388  . 3 
2 KCNK7 1.8  7 .081  .  48 T PV6 1.9   .576  .65 
3 S NN A 4 0.07  . 8 49 CLI 2 2.    .3 9  .87 
4 SCNN B 4 4 313  .  0 SCN3A 2.2   .3 2  . 4 
5 GABRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 GJB5 3 4 3 277  . 7 2 CAC G4 2.6   .31   . 4 
7 CLIC1 9 2 1 738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CN 11 5.    29  . 0 
1 VDAC1 .   −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 3 2.1  −10 53  . 6 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.39   .  
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .   −9 2.311  .  1 RI 2  6.7  −  1 922  .  
16 YR1 .8  9 0.2414  . 1 2 CL C  6.8   0.671  . 9 
17 GJA1 2.1  9 .08   .98 3 CA A S 7.7   1.91  . 7 
18 KCNJ13 1.    .2 6  . 6 4 ATSPE 2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.96 58 TRPC1 5.4 × 10−3 0.665
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO  8.7  18 . 1  . 8 47 CAC B2 1.5  −3 0.4388  . 3 
2 CNK7 1.8  7 .081  .  48 T PV6 1.9   0.576  .65 
3 S NN A 0 4 0.07  . 8 49 CLIC2 2.    .319  .87 
4 S NN B 4 4 313  . 6 0 SCN3A 2.2   .3 2  . 4 
5 G BRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 JB5 3 4 3 277  . 7 2 CAC G4 2.6   1.31   . 4 
7 CLIC1 1 9 2 1.738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CACNA11 5.    0 629  . 0 
1 VDAC1 .0  −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 GJB3 2.   −10 53  .96 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.396  . 4 
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .1  −9 2.311  .  1 RIN2D 6.7  −  1.922  .  
16 RYR1 .8  9 0.2414  . 1 2 CLIC4 6.8   0.671  . 9 
17 GJA1 2.1  9 .086  .98 3 CA A S 7.7   1.91  . 7 
18 K NJ13 1.    .266  . 6 4 CATSPER2 8.1  −3 0.677  . 5 
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.70
13 KCNN2 3.6 10−10 4.3 7
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1 KCNJ1  3.   −6 .388  .80 77 CHR 1 2.1   0.754  . 8 
32 KCNJ18 3 5 −6 0 388 78 ANO  2 4 1 0 67 68
33 TRPM4 3.6  6 .1 4  .87 79 CHRNB2 2.6  1 -  1.383  .70 
34 K S3 7.7  6 . 0   .93 0 SCNN G 2.8  1 -  1.45  . 7 
35 PKD2L1 8 7 6 2.66 86 1 TRP 6 2 8 - 0 5 4
36 P2RX4 1.0  5 1.756  .85 8  K NA1 3.0   0.79  .67 
37 GRIK2 3.9  5 3.922  .86 83 PKD2L2 3.0  1  0.44   .52 
38 KCNJ4 .   5 2.87  .84 84 GAB A6 3.9 × 0−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 .219  0.93 85 GRINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 0−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2  2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.91 59 TRPC7 5.7 × 10−3 1.39
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 KD2L1 8.7 × 10−6 2. 6  0.86 81 TRP 6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 K NA1 3.0 × 10−2 0.79  0.67 
37 G IK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.21  0.93 85 RINB  3.9 × 10−2 1.225  0.67 
40 L 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.3   0.72 
41 MCO 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2  .6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.  × 10−4   0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
.74
14 QP1 5.5 10−10 0.268
Cancers 2019, 11, x 6 of 2  
Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





 ANO1 .7  10−18 0. 1  0.98 47 2 1.5  10−3 0.4388  0.73 
2 K7 .8  −17 .081  .  48 T PV6 1.9  −3 .5 6  .6  
3 SCNN1A .0  10−14 0.07  0. 8 49 CLI 2 2.   10−3 .3 9  0.87 
4 SCNN1B .   4 0.31   .  0 SCN3A 2.2  −3 .382 . 4 
5 GABRE .3  −13 .203  .  1 GRI 2A 2.3  −3 .619 . 9 
6 GJB5 3.4  10−13 0.1277  0.97 52 CACNG4 2.6  10−3 .31   0. 4 
7 CLIC1 .9  −12 1.738  . 5 53 BRB1 3.   −3 .698  .  
8 KCND3 2.0  10−11 0.487  0. 4 54 JB  3.7  10−3 .588  0.63 
9 KCNK1 8.6  10−11 0.269  0. 3 55 CACNB4 4.3  10−3 0.474 0. 6 
0 G IA1 8.7  −11 0.1049  . 3 56 C 1 5.   −  . 2  . 0 
1 VDAC1 .   10−10 1.8  0.96 57 KCNK2 5.   10−3 .512 0. 4 
12 3 2.1 × 10−10 0.2453  0. 6 58 T P 1 5.4  10−3 0.665  0.70 
13 KCNN2 .   -10 4.337  .91 59 7 5.7  −  .39  .  
14 1 5.5 × 10−10 0.2 8  0.84 0 G IK1 6.3  10−3 1.885 0.72 
15 ITPR3 .   −9 2.311  .  1 GRI 2  6.7  −3 1.922  .  
16 YR1 .8  −9 0.2414  . 1 62 CL C  6.8  −3 0.671  . 9 
17 GJA1 2.1  −9 .08   .98 63 CA A S 7.7  −3 1.91  . 7 
18 KCNJ13 1.   −8 .2 6  . 6 64 ATSPE 2 8.1  −3 .677  . 5 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.84 60 RIK1 6.3 × 10−3 1.885
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P RX4 1.0 × 10−5 1.756  0.85 82 K NA1 3.0 × 10−2 0.79  0.67 
37 G IK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 L 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 M O 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2  2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2.097  0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
0.72
15 ITPR3 1.1 × 10−9 2.311
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRN 2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1  2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 . 19  0.93 85 GRINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.93 61 GRI 2D 6.7 × 10−3 1.9 2
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31 KCNJ12 3.5  −6 0.388  .80 77 CHRNB1 2.   −2 0.754  . 8 
32 K NJ18 .5  −6 0.388  .80 78 NO2 2.4  −2 0.67  .68 
33 TRPM4 3.6  −6 0.154  .87 79 CHRN 2 2.6  -2 1.383  .70 
34 KCNS3 7.7  10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 KD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 GRINB2 3.9 × 10−2 1.225  0.67 
40 L 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LR 8D 2.8 × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
0.7
16 RYR1 1.8 × 10−9 0.2414
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





 ANO1 .7 × 10−18 0. 31  0.98 47 2 1.5 × 10−3 0.4388  0.73 
2 K7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCN 1A 1.0 × 10−14 0.07  0. 8 49 CLIC2 2.0 × 10−3 0.3 9  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.9  0 SC 3A 2.2 × 10−3 .382  0.64 
5 GABRE 2.3 × 10−13 0.203  0. 5 1 GRI 2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CAC G4 2.6 × 10−3 .317  0. 4 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 ABRB1 3.0 × 10−3 0.698  0.69 
8 KC D3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 .588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0. 3 55 CACNB4 4.3 × 10−3 0.474  0.66 
0 GRIA1 8.7 × 10−11 0.1049  0.93 56 C A11 5.0 × 10−3 0. 29  0.70 
1 VDAC1 2.  × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0. 4 
12 J 3 2.1 × 10−10 0.2453  0. 6 58 TRP 1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRP 7 5.7 × 10−3 1.39   0.7  
14 QP1 5.5 × 10−10 0.268  0.84 0 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.   −9 2.311  .93 1 GRI 2  6.7  −3 1.922  .75 
16 YR1 1.8  −9 0.2414  .81 62 CLIC  6.8  −3 0.671  . 9 
17 GJA1 2.1  −9 .08   .98 63 CACNA1S 7.7  −3 1.91  . 7 
18 KCNJ13 1.   −8 .2 6  .86 64 ATSPER2 8.1  −3 .677  .75 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.81 62 CLIC4 6.8 × 10−3 0.671
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Table 2. List of ion channels genes howing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 .7 × 10−18 0. 31  0.98 47 2 1.5 × 10−3 0.4388  0.73 
2 K7 1.8 × 10−17 0.081  0.94 48 T PV6 1.9 × 10−3 0.576  0.65 
3 S N 1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.3 9  0.87 
4 S NN1B 1.4 × 10−14 0.313  0.9  0 SC 3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 1 GRI 2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CAC G4 2.6 × 10−3 .317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.0 × 10−3 0.698  0.69 
8 KC D3 2.0 × 10−11 0.487  0.94 54 JB4 3.7 × 10−3 .588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0. 3 55 CACNB4 4.3 × 10−3 0.474  0.66 
0 G IA1 8.7 × 10−11 0.1049  0.93 56 C 11 5.0 × 10−3 0. 29  0.70 
1 VDAC1 2.  × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 J 3 2.  × 10−10 0.2453  0. 6 58 T P 1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 C7 5.7 × 10−3 1.39   0.7  
14 1 5.5 × 10−10 0.268  0.84 0 G IK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.  × 10−9 2.311  0.93 1 GRI 2  6.7 × 10−3 1.922  0.75 
16 YR1 1.8 × 10−9 0.2414  0.81 62 CLIC  6.8 × 10−3 0.671  0. 9 
17 GJA1 2.1 × 10−9 0.08  0.98 63 CA A1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.2 6  0.86 64 ATSPER2 8.1 × 10−3 .677  0.75 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
17 GJA1 2.1 × 10−9 0.086
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





 ANO1 8.7 × 10 8 . 31  0.98 47 CACNB2 1.5 × 10  0.4388  0.73 
2 K7 1 8 × 7 0.081 4 48 T PV6 1 9 × 0 576 65
3 S N A 1.0 × 10 4 0.07  0.98 49 CLIC2 2.0 × 10  0.319  0.87 
4 SCNN1B 1 4 × 4 313 96 0 SC 3A 2 2 × 0 3 2 4
5 GABRE 2 3 × 3 03 95 1 GRI 2A 2 × 619  69
6 GJB5 3 4 × 10 3 277 0 97 2 C C G4 2 6 × 10 3 1 317  0 74
7 CLIC1 1 9 × 2 1.738 5 3 BRB1 3 0 × 0 698  69
8 KC D3 0 1 0.487 94 4 JB4 3 7 × 588 63
9 K1 8 6 × 10− 1 0 269 0 3 5 CACNB4 4 3 × 10 3 0 474  0 66
0 G IA1 8 7 1 0.1049 93 56 AC A11 5 0 × 0 629  0
1 VDAC1 2.0 × 10−10 1.8 0 96 57 KCNK2 5 0 × 10 0 51 0 64
2 GJB3 2.1 × 10−10 . 53  0.96 58 T P 1 5.4 × 10  . 65  0.70 
3 KCNN2 3.6 × 10-10 4 337 0 1 59 7 5 × 10 1.396 0 74
4  5.5 × 10−10 0 68 0 84 0 G IK1 6 3 × 10 1 885 0 72
5 IT R3 1 1 × 10 9 2.311 0 93 1 RIN2D 6 7 × 10 1.922 0 75
16 RYR1 1 8 × 10 9 0.2414 0 81 2 CLIC4 6 8 × 10 0.671 0 9
17 GJA1 2 1 × 10 9 0 086 0 98 3 CA A1S 7 7 × 10 1.91 0 77
18 KCNJ13 1 9 × 10 0 266 0 86 4 CATSPER2 8 1 × 10 3 0.677 0 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357  
1 CLIC3 4.0  8 .118  . 5 67 KCNJ15 9.0  3 .506  .64 
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63  9
3 HCN2 2.1  7 .88  .89 69 SCNN1D .0   0.735  .69 
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.98 63 A A S 7.7 × 10−3 1.91
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1 KCNJ 2 3 5 0.388 0 77 CHRNB1 1 − 75 8
2 KCNJ18 3 5 6 0 388 0 78 ANO2 2 4 67 8
3 TRPM4 6 6 0 15 7 79 CHRN 2 2 6 - 1 383 70
4 NS3 7 6 0. 03 93 0 SCNN1G 2 8 - 1.45 7
5 PKD2L1 8 7 −6 2.66 86 1 T P 6 2 8 - 0 594
36 P2RX4 0 −5 6 5 2 A1 3 0 7 67
37 GRIK2 3.9  5 3.9   .86 3 PKD2L2 3.    0.447  .52 
38 K J4 5 0 5 2.87 84 4 G B A6 3 9 0.622 5
39 TRPM  6 5 -5 0.219 93 5 GRINB2 3 9 225
0 CLCN7 1 2 - 1.753 80 86 K J2 0 1.33 2
1 MCOLN3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 6 0.483 1 88 ASIC1 4.1 × 10−2 0.71 0.63 
43 LRR 8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.09   0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
0.77
18 K NJ13 1.9 × 10−8 0.26
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value  The analysis w s carried out in the 








AUC No. Gene ame 





 ANO1 .7 × 10−18 0. 31  0.98 47 2 1.5 × 10−3 0.4388  0.73 
2 K7 1.8 × 10−17 0.081  0.94 48 T PV6 1.9 × 10−3 0.576  0.65 
3 SCN 1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.3 9  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.9  0 SC 3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 1 GRI 2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 C C G4 2.6 × 10−3 .317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.0 × 10−3 0.698  0.69 
8 KC D3 2.0 × 10−11 0.487  0.94 54 JB4 3.7 × 10−3 .588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0. 3 55 CACNB4 4.3 × 10−3 0.474  0.66 
0 G IA1 8.7 × 10−11 0.1049  0.93 56 C A11 5.0 × 10−3 0. 29  0.70 
1 VDAC1 2.  × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 J 3 2.1 × 10−10 0.2453  0. 6 58 T P 1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 7 5.7 × 10−3 1.39   0.7  
14 1 5.5 × 10−10 0.268  0.84 0 G IK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.  × 10−9 2.311  0.93 1 GRI 2  6.7 × 10−3 1.922  0.75 
16 YR1 1.8 × 10−9 0.2414  0.81 62 CLIC  6.8 × 10−3 0.671  0. 9 
17 GJA1 2.1 × 10−9 0.08   0.98 63 CA A1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.2 6  0.86 64 ATSPER2 8.1 × 10−3 .677  0.75 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.86 64 CATSPER2 8.1 × 10−3 0.677
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 .7 × 10−18 0. 31  0.98 47 2 1.5 × 10−3 0.4388  0.73 
2 CNK7 1.8 × 10−17 0.081  0.94 48 T PV6 1.9 × 10−3 .576  0.65 
3 S N 1A 1.  × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.3 9  0.87 
4 S NN1B 1.4 × 10−14 0.313  0.  0 SC 3A 2.2 × 10−3 0.382  0.64 
5 G BRE 2.3 × 10−13 0.203  0.95 1 GRI 2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 C C G4 2.6 × 10−3 .317  0.74 
7 LIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.0 × 10−3 0.698  0.69 
8 KC D3 2.0 × 10−11 0.487  0.94 54 JB4 3.7 × 10−3 .588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0. 3 55 CACNB4 4.3 × 10−3 0.474  0.66 
0 G IA1 8.7 × 10−11 0.1049  0.93 56 CNA11 5.0 × 10−3 . 29  0.70 
1 VDAC1 2.   10−10 1.8  0.96 57 KCNK2 5.0  10−3 0.512  0.64 
12 J 3 2.  × 10−10 0.2453  0. 6 58 T PC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 C7 5.7 × 10−3 1.39   0.7  
14 1 5.5 × 10−10 0.268  0.84 0 G IK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.  × 10−9 2.311  0.93 1 GRI 2  6.7 × 10−3 1.922  0.75 
16 YR1 1.8 × 10−9 0.2414  0.81 62 CLIC  6.8 × 10−3 0.671  0. 9 
17 GJA1 2.1 × 10−9 0.08  0.98 63 CA A1S 7.7 × 10−3 1.91  0.77 
18 K NJ13 1.9 × 10−8 0.2 6  0.86 64 ATSPER2 8.1 × 10−3 .677  0.75 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.75
19 TRPV2 3.0 × 10−8 1.77
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1 KCNJ1  3.   −6 0.388  .80 77 CHR 1 2.1  −2 0.754  . 8 
32 KCNJ18 3.5  −6 0.388  .  78 ANO  2.4  1 −2 0.67  .68 
33 TRPM4 3.6  −6 .1   .87 79 CHRN 2 2.6  -2 1.383  .70 
34 K S3 7.7  −6 . 0   .93 0 SCNN G 2.8  -2 1.45  . 7 
35 PKD2L1 8.7  −6 2.66  .86 1 TRP 6 2.8  -2 0.5 4  .  
36 P2RX4 1.0  −5 1.756  .85 82 KCNA1 3.0  −2 0.7   .67 
37 GRIK2 3.9  −5 3.9 2  .86 83 PKD2 2 3.0  −2 0.44   .52 
38 KCNJ4 .   −5 2.87  .84 84 GAB A6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 . 19  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 CLCN7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 0−2 1.33  0.72 
41 MCOLN3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 0−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 0−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 0−2 2. 9   0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.88 65 P 8.1 × 10−3 0.3014
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 31 8 47 CACNB2 1 5 0.4388 73
2 K7 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S N A 0 4 0.07 8 49 CLIC2 2 319 87
4 S NN1B 1 4 4 313 6 0 SCN3A 2 2 0 3 2 4
5 G BRE 2 3 3 03 95 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 C C G4 2 6 1 317 4
7 LIC1 1 9 2 1.738 5 3 BRB1 3 698 9
8 KC D3 0 1 0.487 94 4 JB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 G IA1 8 7 1 0.1049 93 56 AC 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KCNK2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 T P 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 C7 5 1.396 4
4  5.5  −10 68 4 0 G IK1 6 3 1 885 2
5 IT R3 1 1 × 10 9 2.311 0 93 1 RIN2D 6 7 × 10 1.922 0 75
16 RYR1 1 8 × 10 9 0.2414 0 81 2 CLIC4 6 8 × 10 0.671 0 9
17 GJA1 2 1 × 10 9 0 086 0 98 3 CA A1S 7 7 × 10 1.91 0 77
18 K NJ13 1 9 × 10 0 266 0 86 4 CATSPER2 8 1 × 10 3 0.677 0 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
20 GJB1 3.4 × 10−8 2.643
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.  × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 K NJ18 3.5 × 10−6 0.388  0.80 78 NO  2.4 × 10−2 0.67 0.68 
33 TRPM4 3.6 × 10−6 0.15   0.87 79 CHRNB2 2.  × 10-2 1.383 0.70 
34 KCNS3 7.7 × 10−6 0. 03  0.93 80 S NN1  2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.  × 10-2 0.594 0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 8  KCNA1 3.0 × 10−2 0.7  0.67 
37 GRIK2 3.9 × 10−5 3.9 2  0.86 83 PKD2 2 3.0 × 10−2 0.447 0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.  × 10−2 0.622 0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RI B2 3.9 × 10−2 1.225  0.67 
40 CLCN7 1.  × 10-4 1.753  0.80 86 K J2 4.0 × 10−2 1.33  0.72 
41 MCO N3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A I 1 4.  × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1 39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CL 6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 9   0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.93 66 J 4 9. × 10−3 0.5357
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 8.7  10−18 0.231  0.98 47 CACNB2 1.5  10−3 0.4388  0.73 
2 K7 .8  10−17 0.081  0.94 48 TRPV6 1.9  10−3 0.576  0.65 
3 SCN 1A .0 × 10−14 0.07  0.98 49 CLIC2 2.0  10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 S 3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRI 2A 2.3  10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 C C G4 2.6 × 10−3 1.317  0.74 
7 LIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.0 × 10−3 0.698  0.69 
8 KC D3 2.0 × 10−11 0.487  0.94 54 JB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 G IA1 8.7 × 10−11 0.1049  0.93 56 AC 11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.  × 10−10 0.2453  0.96 58 T P 1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 C7 5.7 × 10−3 1.396  0.74 
14 1 5.5 × 10−10 0.268  0.84 60 G IK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CA A1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
21 CLIC3 4.0 × 10−8 0.118
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to th  AUC value  The analysis w s carried out in the 








AUC No. Gene ame 





1 NO1 8 7 8 31 8 47 CACNB2 1 5 0.4388 73
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S N A 0 4 0.07 8 49 CLIC2 2 319 87
4 SCNN1B 1 4 4 313 6 0 S 3A 2 2 0 3 2 4
5 GABRE 2 3 3 03 95 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 C C G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 BRB1 3 698 9
8 KC D3 0 1 0.487 94 4 JB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 G IA1 8 7 1 0.1049 93 56 AC 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KCNK2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 T P 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 C7 5 1.396 4
4  5.5  −10 68 4 0 G IK1 6 3 1 885 2
5 IT R3 1 1 × 10 9 2.311 0 93 1 RIN2D 6 7 × 10 1.922 0 75
16 RYR1 1 8 × 10 9 0.2414 0 81 2 CLIC4 6 8 × 10 0.671 0 9
17 GJA1 2 1 × 10 9 0 086 0 98 3 CA A1S 7 7 × 10 1.91 0 77
18 KCNJ13 1 9 × 10 0 266 0 86 4 CATSPE 2 8 1 × 10 3 0.677 0 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.85 67 J15 9. × 10−3 0.506
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 8 7 8 31 8 47 CACNB2 1 5 0.4388 73
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLIC2 2 319 87
4 S NN1B 1 4 4 313 6 0 S 3A 2 2 0 3 2 4
5 G BRE 2 3 3 03 95 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 C C G4 2 6 1 317 4
7 LIC1 1 9 × 2 1.738 5 3 BRB1 3 × 698 9
8 KCND3 0 1 0.487 94 4 JB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 G IA1 8 7 1 0.1049 93 56 AC 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KCNK2 5 0 0 51 64
2 GJB3 2.   −10 53 96 58 T P 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 C7 5 1.396 4
4  5.5  −10 68 4 0 G IK1 6 3 1 885 2
5 IT R3 1 1 × 10 9 2.311 0 93 1 RIN2D 6 7 × 10 1.922 0 75
16 RYR1 1 8 × 10 9 0.2414 0 81 2 CLIC4 6 8 × 10 0.671 0 9
17 GJA1 2 1 × 10 9 0 086 0 98 3 CA A1S 7 7 × 10 1.91 0 77
18 K NJ13 1 9 × 10 0 266 0 86 4 CATSPER2 8 1 × 10 3 0.677 0 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.64
22 LRRC8B 4.4 × 10−8 0.459
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to th  AUC value  The analysis w s carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 98 47 2 1 5 0.4388 73
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 SCNN1A 1 0 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 0.313 9 0 S 3A 2 2 382 64
5 GABRE 2 3 − 3 0 203 5 1 GRI 2A 2 3 0 619 69
6 GJB5 3 4 3 0.1277 97 52 C C G4 2 6 317 4
7 CLIC1 .9 × 10−12 1 738 0 5 53 ABRB1 3 0 × 10 0 698 0 69
8 KCND3 2.0 × 10−11 0.487 0 94 54 GJB4 3 7 × 0 588 0 63
9 KCNK1 8.6 × 10−11 0 269 0 3 55 CACNB4 4 3 × 10 0.474 0 66
0 GRIA1 8.7 × 10−11 0.1049 0 93 56 C A11 5 0 × 10 0 29 0 0
1 VDAC1 2.  × 10−10 1.8 0 96 57 KCNK2 5 0 × 10 0.512 0 4
12 3 2.1 × 10−10 0.2453 0 6 58 TRP 1 5 4 × 10 0.665 0 70
13 KCNN2 3.6 × 10-10 4 337 0 91 59 TRP 7 5 7 × 10 1 39 0 7
14 QP1 5.5 × 10−10 0 268 0 84 0 GRIK1 6 3 × 10 3 1.885 0 72
15 ITPR3 1 9 2.311 93 1 GRI 2  6 7 3 1 922 75
16 YR1 1 8 9 0.2414 81 62 CL C  6 8 3 0.671 9
17 GJA1 2 1 9 08 98 63 CACNA1S 7 7 3 1.91 7
18 KCNJ13 1 8 2 6 86 64 ATSPE 2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.90 68 CNGB3 1. × 10−2 0.63
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 8 47 2 1 5 0.4388 73
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S N A 0 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 S 3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 LIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KC D3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 C 11 5 0 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.   −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1 39
4 QP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
23 HCN2 2.1 × 10−7 3.88
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1 KCNJ12 3 0.388 0 77 CHRNB1 1 − 75 8
2 KCNJ18 3 5 6 0 388 0 78 ANO2 2 4 67 8
3 TRPM4 6 6 0 15 7 79 CHRN 2 2 - 1 38 70
4 NS3 7 7 6 0.403 93 0 S NN1 2 8 - 1.4  7
5 PKD2L1 8 7 −6 2.66 86 1 T P 6 2 - 0 594
36 P2RX4 0 −5 6 5 NA1 3 0 79 67
37 GRIK2 3 9 5 3 92 86 3 PKD2 2 3 0.44  52
38 K J4 5 0 5 2.87 84 4 G BRA6 3 0.622 5
39 TRPM2 6 5 -5 0.219 93 5 RI B  3 9 225
0 CL 7 1 - 1.753 80 86 K J2 0 1.3  2
1 MCO N3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 2 6 0.483 1 88 ASIC1 4.  × 0−2 0.71 0.63 
43 LRR 8D 2.  × 10−4 1.39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL 6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 0−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.8 69 SCN 1D 1. × 10−2 0.735
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 8 7 8 31 8 47 CACNB2 1 5 0.4388 3
2 K7 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 SCN A 0 4 0.07 8 49 CLIC2 2 319 87
4 S NN1B 1 4 4 313 6 0 S 3A 2 2 3 2 4
5 G BRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 C C G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KC D3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 AC 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.   −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 QP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 K NJ13 1 9 266 86 4 CATSPER2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.69
24 TRPM1 3.0 × 10−7 0.3 8
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 8 47 2 1 5 0.4388 3
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S N A 0 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 S 3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 C C G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KC D3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 C A11 5 0 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.1  −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1 39
4 QP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPE 2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.77 70 RI 4 1.2 × 10−2 0.71
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Table 2. List of ion channels genes showing differ ntial expression i  nev  vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 8 47 2 1 5 0.4388 3
2 K7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S N A 0 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 S 3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 JB5 3 4 3 277 7 2 C C G4 2 6 317 4
7 LIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KC D3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 C 11 5 0 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.   −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1 39
4 QP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
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25 BEST2 3.6 × 10−7 0.456
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 




t Test Nevi vs. 
Melanoma 
Ratio elano a 
vs. Nevi 
AUC No. Gene Name 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.86 71 TRPM3 1.3 × 10−2 0.762
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 




t Test Nevi vs. 
Melanoma 
Ratio elano a 
vs. Nevi 
AUC No. Gene Name 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 S NN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.  × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.72
26 AQP3 6.9 × 10−7 0.067
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 .231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.97 72 HRNA10 1.5 × 10−2 0.759
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 S NN1A 1.0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.  × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
27 KCNN4 1.5 × 10−6 3.79
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 8  KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 CLCN7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOLN3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 ASIC1 4.1 × 10−2 0.71  0.63 
43 LRRC8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 CNGA1 5.0 × 10−4 0.58  0.72       
  
0.93 73 AQP9 1.9 × 10−2 0.56
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 KCNK7 .8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A .0 × 10−14 0.07  0.98 49 CLIC2 2.0 × 10−3 0.319  0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382  0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619  0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACNA11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.75
28 SCN1B 1.5 × 10−6 0.657
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene Name 





1 ANO1 8 7 8 31 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLI 2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACN 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPE 2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.83 74 VD C3 1.9 × 10−2 1.27
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B .6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRRC8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
.78
29 LR C8E 1.5 × 10−6 0.563
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 
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1 ANO1 8 7 8 1 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLI 2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACN 11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPE 2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.82 75 KCNV1 2. × 10−2 1.737
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31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.21   0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B .6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRRC8D 2.8 × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
.70
30 CACNB1 2.9 × 10−6 0.614
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.231  0.98 47 CACNB2 1.5 × 10−3 0.4388 0.73 
2 KCNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 0.576  0.65 
3 SCNN1A 1.0 × 10−14 0.07  0.98 49 CLI 2 2.0 × 10−3 0.319 0.87 
4 SCNN1B 1.4 × 10−14 0.313  0.96 50 SCN3A 2.2 × 10−3 0.382 0.64 
5 GABRE 2.3 × 10−13 0.203  0.95 51 GRIN2A 2.3 × 10−3 0.619 0.69 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CACNG4 2.6 × 10−3 1.317  0.74 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0 × 10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 0−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474 0.66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CACN 11 5.0 × 10−3 0.629 0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512 0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRPC7 5.7 × 10−3 1.396 0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885 0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671 0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACNA1S 7.7 × 10−3 1.91 0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 64 CATSPE 2 8.1 × 10−3 0.677 0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357 0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506 0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63 0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.82 76 VDAC2 2. × 10−2 1.15
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRPC6 2.8 × 10-2 0.594  0.67 
36 P RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 GRINB2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 M OL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRRC8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
.71
31 KCNJ12 3.5 × 10−6 0.388
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.1  −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.80 77 HRNB1 2.1 × 10−2 0.754
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN1A 1 4 0.07 8 49 CLIC2 2 3 9 87
4 S NN1B 1 4 4 0.313 0 SCN3A 2 2 382 64
5 GABRE 2 3 − 3 0 203 5 1 GRIN2A 2 3 0 619 69
6 JB5 3 4 3 0.1277 97 52 CACNG4 2 6 317 4
7 CLIC1 .9  −12 1 738 5 53 ABRB1 3 0 0 698 69
8 KCND3 2.0  −11 0.487 94 54 GJB4 3 7 588 3
9 KCNK1 8.6  −11 269 3 55 CACNB4 4 3 0.474 66
0 GRIA1 8.7  −11 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 96 57 KCNK2 5 0 0.512 4
12 3 2.   −10 0.2453 6 58 TRPC1 5 4 0.665 70
13 KCNN2 3.6  -10 4 337 91 59 TRPC7 5 7 1 39 7
14 AQP1 5.5  −10 268 84 0 GRIK1 6 3 3 1.885 72
15 ITPR3 1 9 2.311 93 1 GRI 2  6 7 3 1 922 75
16 YR1 1 8 9 0.2414 81 62 CL C  6 8 3 0.671 9
17 GJA1 2 1 9 08 98 63 CACNA1S 7 7 3 1.91 7
18 KCNJ13 1 8 2 6 86 64 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
32 KCNJ18 3.5 × 10−6 0.388
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN A 4 0.07 8 49 CLIC2 2 3 9 87
4 SCNN1B 1 4 4 313 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.1  −10 53 6 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1 39
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08 98 3 CA A1S 7 7 1.91 7
18 KCNJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.80 78 ANO2 2.4 × 10−2 0.67
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 1 7 8 31 8 47 2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 576 65
3 S NN1A 1 4 0.07 8 49 CLIC2 2 3 9 87
4 S NN1B 1 4 4 0.313 0 SCN3A 2 2 382 64
5 GABRE 2 3 − 3 0 203 5 1 GRIN2A 2 3 0 619 69
6 JB5 3 4 3 0.1277 97 52 CACNG4 2 6 317 4
7 CLIC1 .9  −12 1 738 5 53 ABRB1 3 0 0 698 69
8 KCND3 2.0  −11 0.487 94 54 GJB4 3 7 588 3
9 KCNK1 8.6  −11 269 3 55 CACNB4 4 3 0.474 66
0 GRIA1 8.7  −11 0.1049 93 56 CNA11 5 0 29 0
1 VDAC1 2.   −10 1.8 96 57 KCNK2 5 0 0.512 4
12 3 2.   −10 0.2453 6 58 TRPC1 5 4 0.665 70
13 KCNN2 3.6  -10 4 337 91 59 TRPC7 5 7 1 39 7
14 AQP1 5.5  −10 268 84 0 GRIK1 6 3 3 1.885 72
15 ITPR3 1 9 2.311 93 1 GRI 2  6 7 3 1 922 75
16 YR1 1 8 9 0.2414 81 62 CL C  6 8 3 0.671 9
17 GJA1 2 1 9 08 98 63 CACNA1S 7 7 3 1.91 7
18 KCNJ13 1 8 2 6 86 64 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
33 TRPM4 3.6 × 10−6 0.154
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 8 7 8 31 8 47 CAC B2 1 5 0.4388 73
2 KCNK7 1 8 7 0.081 4 48 TRPV6 1 9 0 576 65
3 S NN A 0 4 0.07 8 49 CLIC2 2 319 87
4 SCNN1B 1 4 4 313 6 0 SCN3A 2 2 3 2 4
5 GABRE 2 3 3 03 5 1 GRI 2A 2 619 9
6 GJB5 3 4 3 277 7 2 CAC G4 2 6 1 317 4
7 CLIC1 1 9 2 1.738 5 3 GABRB1 3 698 9
8 KCND3 0 1 0.487 4 4 GJB4 3 7 588 63
9 K1 8 − 1 0 269 3 5 CACNB4 4 3 0 474 66
0 GRIA1 8 7 1 0.1049 93 56 CACNA11 5 0 0 629 0
1 VDAC1 2.0  −10 1.8 6 57 KC K2 5 0 0 51 64
2 GJB3 2.1  −10 53 96 58 TRP 1 5 4 65 70
3 KCNN2 3.6  -10 4 337 1 59 TRP 7 5 1.396 4
4 AQP  5.5  −10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 1 9 2.311 93 1 RIN2D 6 7 1.922 75
16 RYR  1 8 9 0.2414 81 2 CLIC4 6 8 0.671 9
17 GJA1 2 1 9 086 98 3 CA A1S 7 7 1.91 77
18 KCNJ13 1 9 266 86 4 CATSPER2 8 1 3 0.677 75
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.87 79 HRNB2 2.6 × 10−2 1.383
Cancers 2019, 11, x 7 of 22 
1 KCNJ12 3 5 0.388 0 77 CHRNB1 1 − 75 8
2 KCNJ18 3 5 6 0 388 0 78 ANO2 2 4 67 8
3 TRPM4 6 6 0 154 7 79 CHRNB2 2 6 - 1 383 70
4 S3 7 7 6 0.403 93 0 SCNN1G 2 8 - 1.45 7
5 PKD2L1 8 7 −6 2.66 86 1 T P 6 2 8 - 0 594
36 P2RX4 0 −5 6 5 2 A1 3 0 79 67
37 GRIK2 3 9 5 3 92 86 3 PKD2L2 3 0.447 52
38 K J4 5 0 5 2.87 84 4 G BRA6 3 9 0.622 5
39 TRPM2 6 5 -5 0.2 9 93 5 RINB  3 9 225
0 CLCN7 1 2 - 1.753 80 86 K J2 0 1.3  2
1 MCO N3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 6 0.483 1 88 ASIC1 4.1 × 10−2 0.71 0.63 
43 LRR 8D 2.  × 10−4 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2. 97  0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
.70
34 KCNS3 7.7 × 10−6 0. 0
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388  . 3 
2 KCNK7 1.8  7 .081  .  48 T PV6 1.9   .576  .65 
3 S NN A 4 0.07  . 8 49 CLI 2 2.    .3 9  .87 
4 SCNN B 4 4 313  .  0 SCN3A 2.2   .3 2  . 4 
5 GABRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 GJB5 3 4 3 277  . 7 2 CAC G4 2.6   .31   . 4 
7 CLIC1 9 2 1 738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CN 11 5.    29  . 0 
1 VDAC1 .   −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 3 2.1  −10 53  . 6 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.39   .  
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .   −9 2.311  .  1 RI 2  6.7  −  1 922  .  
16 YR1 .8  9 0.2414  . 1 2 CL C  6.8   0.671  . 9 
17 GJA1 2.1  9 .08   .98 3 CA A S 7.7   1.91  . 7 
18 KCNJ13 1.    .2 6  . 6 4 ATSPE 2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRN 10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.93 80 SCN 1G 2.8 × 10−2 1.45
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1 KCNJ1 3 −6 388 80 77 CHR 1 2 0 754 8
32 KCNJ18 3 5 −6 0 388 78 ANO  2 4 0 67 68
33 TRPM4 3 6 6 1 4 87 79 CHRNB2 2 6 - 1.383 70
34 K S3 7 7 6 0 93 0 SCNN G 2 8 - 1 45 7
35 PK 2L1 8 7 6 2 66 86 1 TRPC6 2 8 - 0 5 4
36 P2RX4 1 0 5 1.756 85 82 K NA1 3 0 0.79 67
37 G IK2 3 9 5 3.922 86 83 PKD2L2 3 0 0 44 52
38 KCNJ4 5 2 87 84 84 GABRA6 3.9 × 10−2 0.622 0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 L 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 MCOL 3 2.  × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2  .6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN  .8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
.67
35 PKD L1 8.7 × 10−6 2.66
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.  × 10−2 0.754 0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 0−2 0.67 0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 0-2 1.383 0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45 0.67 
35 PKD2L1 8.7 × 10−6 2.6   0.86 81 TRP 6 2.8 × 10-2 0.594  0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 K NA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2 2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB  3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 0−2 1.3   0.72 
41 MCO 3 2.  × 10−4 0.352  0.62 87 TRPV5 4.0 × 0−2 1.29  0.66 
42 SCN2  2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 0−2 0.71  0.63 
43 LRR 8  2.  × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN  3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.86 81 TRPC6 2.8 × 10−2 0.594
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7  18 . 1  . 8 47 CAC B2 1.5  −3 0.4388  . 3 
2 CNK7 .8  7 .081  .  48 T PV6 1.9   0.576  .65 
3 S NN A 0 4 0.07  . 8 49 CLIC2 2.    .319  .87 
4 S NN B 4 4 313  . 6 0 SCN3A 2.2   .3 2  . 4 
5 G BRE 3 3 . 03  . 5 1 GRI 2A 2.    619  . 9 
6 GJB5 3 4 3 277  . 7 2 CAC G4 2.6   1.31   . 4 
7 CLIC1 1 9 2 1.738  . 5 3 BRB1 3.    698  .  
8 KCND3 0 1 0.487  . 4 4 B  3.7   588  . 3 
9 K1 8 − 1 .269  . 3 5 CACNB4 4.3   .474  . 6 
0 G IA1 8 7 1 0.1049  . 3 56 CACNA11 5.    0 629  . 0 
1 VDAC1 .0  −10 1.8  . 6 57 KCNK2 5.    .51   . 4 
2 GJB3 2.   −10 53  .96 58 T P 1 5.4  −  65  .70 
3 KCNN2 .   -10 4.337  . 1 59 C7 5.    1.396  . 4 
4  5.5  −10 . 8  . 4 0 G IK1 6.3   1.885  . 2 
5 IT R3 .1  −9 2.311  .  1 RIN2D 6.7  −  1.922  .  
16 RYR1 .8  9 0.2414  . 1 2 CLIC4 6.8   0.671  . 9 
17 GJA1 2.1  9 .086  .98 3 CA A S 7.7   1.91  . 7 
18 K NJ13 1.    .266  . 6 4 CATSPER2 8.1  −3 0.677  . 5 
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357 
1 CLIC3 4 0 8 118 5 67 KCNJ15 9 0 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.67
36 P2RX4 1.0 × 10−5 1.75
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5  6 0.388  .80 77 CHRNB1 2.    0.754  . 8 
32 K NJ18 .5  6 0.388  .80 78 NO  2.4   0.67  .68 
33 TRPM4 3.6  6 0.154  .87 79 CHRNB2 2.6  -  1.383  .70 
34 KCNS3 7.7  −6 0.403  .93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2. 6  0.86 81 TRP 6 2.8 × 10-2 0.594 0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79 0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2 2 3.0 × 10−2 0.447 0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622 0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB  3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.3   0.72 
41 MCO 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A I 1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.  × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.85 82 A1 3. × 10−2 0.79
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO  8.7  −18 0.2 1  . 8 47 CACNB2 1.5  −3 0.4388  . 3 
2 KCNK7 .8  7 .081  .9  48 T PV6 1.9   0.576  .65 
3 SCNN1A .0  −14 0.07  . 8 49 CLIC2 2.0   0.319  .87 
4 S NN B .4  −14 0.313  .96 50 SCN3A 2.2   .382  . 4 
5 GABRE .3  −13 .203  . 5 51 GRI 2A 2.3   0.619  .69 
6 GJB5 3.4  −13 0.1277  .97 52 CACNG4 2.6   1.31   . 4 
7 CLIC1 1.9  −12 1.738  .95 53 BRB1 3.0   0.698  .  
8 KCND3 2.0  −11 0.487  . 4 54 B  3.7   0.588  . 3 
9 KCNK1 8.6  −11 .269  .93 55 CACNB4 4.3   .474  . 6 
10 G IA1 8.7  −11 0.1049  . 3 56 CACNA11 5.   3 0.629  .70 
11 VDAC1 .0  −10 1.8  .96 57 KCNK2 5.   3 .512  . 4 
12 GJB3 2.   −10 0.2453  .96 58 T PC1 5.4  −3 0.665  .70 
13 KCNN2 .   -10 4.337  .91 59 C7 5.7  3 1.396  . 4 
14 1 5.5  −10 .2 8  .84 60 G IK1 6.3  3 1.885  .72 
15 ITPR3 .1  −9 2.311  .  61 GRIN2D 6.7  −3 1.922  .  
16 RYR1 .8  −9 0.2414  . 1 62 CLIC4 6.8  3 0.671  .69 
17 GJA1 2.1  −9 .086  .98 63 CA A S 7.7  3 1.91  . 7 
18 KCNJ13 1.   −8 .266  . 6 64 CATSPER2 8.1  −3 0.677  . 5 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.67
37 G IK2 3.9 × 10−5 3.9 2
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.  × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO  2.4 × 10−2 0.67 0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383 0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1  2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.8 × 10-2 0.594 0.67 
36 P2RX4 1.0 × 10−5 1.756  0.85 8  K NA1 3.0 × 0−2 0.79 0.67 
37 GRIK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 0−2 0.447 0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.9 × 0−2 0.622 0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 GRINB  3.9 × 10−2 1.225  0.67 
40 CL 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.3   0.72 
41 MCO 3 2.  × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2  2.6 × 10−4 0.483  0.71 88 A I 1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.  × 10−4 1 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.86 83 KD2L2 3. × 10−2 0.447
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 . 31  .  47 2 1.5  −3 0.4388  . 3 
2 K7 8 7 .081  . 4 48 TRPV6 1.9  −3 .5 6  .6  
3 SCNN1A 4 0.0   .  49 CLIC2 2.   −3 3 9  .87 
4 S NN1B 1 4 0.31  .  0 SCN3A 2.2  −3 382  . 4 
5 G BRE 2 3 − 3 .203  .  1 GRI 2A 2.3  −3 .619  . 9 
6 GJB5 3 3 0.1277  . 7 52 CACNG4 2.6  −  317  . 4 
7 CLIC1 .9  −12 1 738  . 5 53 ABRB1 3.   −  .698  .  
8 KCND3 2.   −11 .487  .94 54 GJB4 3.7  −  588  . 3 
9 KCNK1 8.   −11 .269  . 3 55 CACNB4 4.   −  .474  .66 
0 GRIA1 8.7  −11 0.1049  . 3 56 C 1 5.0  −  . 2   . 0 
1 VDAC1 2.   −10 1.8  . 6 57 KCNK2 5.0  −  0.512  . 4 
12 3 2.  × 10−10 0.2453  . 6 58 TRP 1 5.4  −  0.665  . 0 
13 KCNN2 3.6  -10 4.337  .91 59 TRPC7 5.7  −  .39   .  
14 QP1 5.5 × 10−10 .268  . 4 0 GRIK1 6.3  −3 1.885  . 2 
15 ITPR3 1 9 2.311 93 1 GRI 2  6 7 3 1 922 75
16 YR1 1 8 9 0.2414 81 62 CL C  6 8 3 0.671 9
17 GJA1 2 1 9 08  98 63 CACNA1S 7 7 3 1.91 7
18 K NJ13 1 8 2 6 86 64 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.52
38 KCNJ4 5.0 × 10−5 2.87
Cancers 2019, 11, x 7 of 22 
1 KCNJ12 3 5 0.388 0 77 CHRNB1 − 75 8
2 KCNJ18 3 5 6 0 388 0 78 ANO2 2 4 67 8
3 TRPM4 6 6 0 154 7 79 CHRNB2 2 6 - 1 383 70
4 NS3 7 7 6 0.403 93 0 SCNN1 2 8 - 1.45 7
5 PKD2L1 8 7 −6 2.66 86 1 T P 6 2 8 - 0 594
36 P2RX4 0 −5 6 5 A1 3 0 79 67
37 GRIK2 3 9 5 3 92 86 3 PKD2L2 3 0.447 52
38 K J4 5 0 5 2.87 84 4 G B A6 3 9 0.622 5
39 TRPM2 6 5 -5 0.219 93 5 GRINB  3 9 225
0 CLCN7 1 2 - 1.753 80 86 K J2 0 1.3  2
1 MCO N3 2 0.352 62 87 V5 0 1.29 6
2 SCN2  2 6 0.483 1 88 ASIC1 4.1 × 10−2 0.71 0.63 
43 LRR 8D 2.  × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 0−2 2. 97  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.84 84 G RA6 3.9 × 10−2 0.6 2
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 7 8 31 47 2 1 5 −3 0.4388 3
2 K7 8 7 .081 4 48 TRPV6 1 9 −3 5 6 6
3 S NN A 4 0.0  49 CLIC2 2 −3 3 9 87
4 S NN1B 1 4 31 0 SCN3A 2 2 −3 3 2 4
5 G BRE 2 3 3 03 1 GRI 2A 2 −3 619 9
6 GJB5 3 3 277 7 2 CAC G4 2 6 − 317 4
7 CLIC1 9 2 1 738 5 3 ABRB1 3 − 698
8 KCND3 1 .487 4 4 GJB4 3 7 588 3
9 K1 8 − 1 269 3 5 CACNB4 4 − 474 66
0 GRIA1 8 7 1 0.1049 3 56 C 1 5 0 − 2 0
1 VDAC1 2.   −10 1.8 6 57 KC K2 5 0 0 51 4
2 3 2.  × 10−10 53 6 58 TRP 1 5 4 − 65 0
3 KCNN2 3.6  -10 4 337 1 59 TRPC7 5 − .39  
4 QP  5.5 × 10−10 8 4 0 GRIK1 6 3 1 885 2
5 IT R3 1 9 2.311 93 1 RI 2  6 7 1 922 75
16 YR  1 8 9 0.2414 81 2 CL C  6 8 0.671 9
17 GJA1 2 1 9 08  98 3 CA A1S 7 7 1.91 7
18 K NJ13 1 2 6 86 4 ATSPER2 8 1 3 677 75
19 TRPV2 3 0 8 1 7 8 5 GABRP 8 1 3 0.3014 
0 GJB  4 8 2 43 9 66 GJ 4 9 0 3 0.5357 
1 CLI 3 4 0 8 118 5 67 J15 9 3 506 64
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 63 9
3 HCN2 2 1 7 88 89 69 SCNN1D 0 0.735 69
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
39 TRPM2 6.5 × 10−5 0.219
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to th  AUC value. The analysis w s carried out in the 








AUC No. Gene ame 





1 ANO1 .7  18 . 1  . 8 47 2 1.5  −3 0.4388 . 3 
2 KCNK7 1.8  7 .081  .  48 T PV6 1.9   .576  .65 
3 SCNN1A 4 0.07  . 8 49 CLI 2 2.    .3 9  .87 
4 SCNN B 4 4 0.313  .  0 SCN3A 2.2   .382 . 4 
5 GABRE 3 − 3 .203  . 5 1 GRI 2A 2.3   0 619 .69 
6 GJB5 3 4 3 0.1277  .97 52 CACNG4 2.6   .31   . 4 
7 CLIC1 .9  −12 1 738  . 5 53 BRB1 3.0   0 698  .  
8 KCND3 2.0  −11 0.487  . 4 54 B  3.7   588  . 3 
9 KCNK1 8.6  −11 .269  . 3 55 CACNB4 4.3   .474 . 6 
0 G IA1 8.7  −11 0.1049  . 3 56 CN 11 5.    29 . 0 
1 VDAC1 .   −10 1.8  .96 57 KCNK2 5.    .512  . 4 
12 3 2.1  −10 0.2453  . 6 58 T PC1 5.4  −  0.665  .70 
13 KCNN2 .   -10 4.337  .91 59 C7 5.7   1.39  .  
14 1 5.5  −10 .2 8  .84 0 G IK1 6.3  3 1.885 .72 
15 ITPR3 .   −9 2.311  .  1 GRI 2  6.7  −3 1 922  .  
16 YR1 .8  9 0.2414  . 1 62 CL C  6.8  3 0.671  . 9 
17 GJA1 2.1  9 .08   .98 63 CA A S 7.7  3 1.91  . 7 
18 KCNJ13 1.   8 .2 6  . 6 64 ATSPE 2 8.1  −3 677  . 5 
19 TRPV2 3 0 8 1 7 88 65 GABRP 8 1 3 0.3014 69
0 GJB  3 4 −8 2 43 9 66 GJ 4 9 0 3 0.5357 6
1 CLI 3 4 0 −8 118 5 67 J15 9 3 0 506 64
22 LRRC8B 4 4 −8 459 90 68 CNGB3 1 0 63 69
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.93 85 GRINB2 3.9 × 10−2 1.2 5
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1 KCNJ1 3.   6 388  .80 77 CHR 1 2.    0.754  . 8 
32 K NJ18 .5  6 0 388  .  78 NO  2.4   0 67  .68 
33 TRPM4 3.6  6 1 4  .87 79 CHRNB2 2.6  -  1.383  .70 
34 K S3 7.7  −6 0  .93 0 SCNN G 2 8  - 1 45  7
35 PKD2L1 8 7 6 2.66 86 1 TRP 6 2 8 - 0 5 4
36 P RX4 1 0 5 1.756 85 82 KCNA1 3 0 0.79 67
37 G IK2 3 9 5 3.922 86 83 PKD2L2 3 0 0 44 52
38 KCNJ4 5 2 87 84 84 GAB A6 3.9 × 10−2 0.622 0.65 
39 TRPM2 6.5 × 10-5 0.21  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 L 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 M OL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRRC8D 2.8 × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 .8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2. 97  0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
.67
40 CLCN7 1.2 × 10−4 1.75
Cancers 2019, 11, x 7 of 22 
1 KCNJ12 3 5 0.388 0 77 CHRNB1 1 −  75  8
2 KCNJ18 3 5 6 0 388 0 78 ANO2 2 4 1 67 8
3 TRPM4 6 6 0 154 7 79 CHRNB2 2 6 1 - 1 383  70
4 NS3 7 7 6 0.403 93 0 SCNN1G 2 8 1 - 1.45  7
5 PKD2L1 8 7 −6 2.66 86 1 T P 6 2 8 - 0 594
36 P2RX4 0 −5 6 5 A1 3 0 79 67
37 GRIK2 3 9 5 3 92 86 3 PKD2 2 3 0.447 52
38 K J4 5 0 5 2.87 84 4 G B A6 3 9 0.622 5
39 TRPM2 6 5 -5 0.219 93 5 GRINB  3 9 225
0 CLC 7 1 2 - 1.753 80 86 K J2 0 1.3  2
1 MCO N3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 2 6 0.483 1 88 ASIC1 4.1 × 0−2 0.71 0.63 
43 LRR 8D 2.  × 10−4 39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.  × 10−4 1.43  0.72 90 CAC G3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.80 86 J2 4. × 10−2 1.3
Cancers 2019, 11, x 7 of 22 
1 KCNJ1  3.   −6 .388  .80 77 CHR 1 2.1   0.754  . 8 
32 KCNJ18 3 5 −6 0 388 78 ANO  2 4 0 67 68
33 TRPM4 3.6  6 .1 4  .87 79 CHRNB2 2.6  -  1.383  .70 
34 K S3 7.7  6 . 0  .93 0 SCNN G 2.8  -  1.45  . 7 
35 KD2L  8 7 6 2 66 86 1 TRPC6 2 8 - 0 5 4
36 P RX4 1.0  5 1.756  .85 82 K NA1 3.0   0.79  .67 
37 G IK2 3.9  5 3.922  .86 83 PKD2L2 3.0   0.44   .52 
38 KCNJ4 .   5 2.87  .84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 RINB2 3.9 × 10−2 1.225  0.67 
40 LC 7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 M OL 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1. 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CAC G3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2.097  0.69 
46 CNGA1 5.0 × 10−4 0.58  0.72       
  
0.72
41 MCOLN3 2.2 × 10−4 0.352
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Table 2. List of ion channels genes showing differential expression i  nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7 × 10−18 0.2 1  0.98 47 CACNB2 1.5 × 10−3 0.4388  0.73 
2 K7 .8 × 10−17 0.081  0.9  48 T PV6 1.9 × 10−3 .5 6  0.6  
3 SCN 1A .0 × 10−14 0.07  0. 8 49 LI 2 2.0 × 10−3 0.319  0.87 
4 SCNN1B .  × 10−14 0.31   0. 6 50 SCN3A 2.2 × 10−3 .382 0.64 
5 GABRE .3 × 10−13 0.203  0.  51 G I 2A 2.3 × 10−3 0.619  0. 9 
6 GJB5 3.4 × 10−13 0.1277  0.97 52 CAC G4 2.6 × 10−3 1.31   0. 4 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.  × 10−3 .698  0.  
8 K D3 2.0 × 10−11 0.487  0. 4 54 JB  3.7 × 10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 0.269  0.93 55 CACNB4 4.3 × 10−3 0.474  0. 6 
10 G IA1 8.7 × 10−11 0.1049  0. 3 56 AC 1 5.0 × 10−3 .62   0.70 
11 VDAC1 .0  10−10 1.8  0.96 57 KCNK2 5.   10−3 .512 0. 4 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 T P 1 5.4  10−3 0.665  0.70 
13 KCNN2 .   -10 4.337  .91 59 7 5.7  −3 .396 . 4 
14 1 5.5 × 10−10 0.2 8  0.84 60 G IK1 6.3  10−3 1.885 0.72 
15 ITPR3 .1  −9 2.311  .  61 GRIN2D 6.7  −3 1.922  .  
16 RYR1 .8  −9 0.2414  . 1 62 CLIC4 6.8  −3 0.671  .69 
17 GJA1 2.1  −9 .086  .98 63 CA A S 7.7  −3 1.91  . 7 
18 KCNJ13 1.   −8 .266  . 6 64 CATSPE 2 8.1  −3 0.677  . 5 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71 0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762 0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRN 10 1.5 × 10−2 0.759 0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.62 87 TRPV5 4. × 10−2 1.29
Cancers 2019, 11, x 7 of 22 
31 KCNJ12 3.5 × 10−6 0.388  0.80 77 CHRNB1 2.1 × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.154  0.87 79 CHRNB2 2.6 × 10-2 1.383  0.70 
34 KCNS3 7.7 × 10−6 0.403  0.93 80 SCNN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.8 × 10-2 0.594  0.67 
36 P RX4 1.0 × 10−5 1.756  0.85 82 K NA1 3.0 × 10−2 0.79  0.67 
37 G IK2 3.9 × 10−5 3.922  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KC J4 5.0 × 10−5 2.87  0.84 84 GABRA6 3.9 × 10−2 0.622  0.65 
39 TRPM2 6.5 × 10-5 0.219  0.93 85 GRINB2 3.9 × 10−2 1.225  0.67 
40 LCN7 1.2 × 10-4 1.753  0.80 86 KCNJ2 4.0 × 10−2 1.33  0.72 
41 M O 3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A IC1 4.1 × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CL N6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.  × 10−2 2.097  0.69 
46 C A1 5.0 × 10−4 0.58  0.72       
  
0.66
42 SCN2B 2.6 × 10−4 0. 8
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7  10 18 0. 1  0.98 47 CACNB2 1.5  10−3 0.4388  0.73 
2 K7 .8  −17 .081 48 T PV6 1 9 −3 5 6 6
3 S NN A .0  10 4 0.07  0. 8 49 CLIC2 2.   10−3 .319  0.87 
4 SCNN1B 4 31 6 0 SCN3A 2 2 −3 .3 2 4
5 GABRE 3 3 03 1 GRI 2A 2 −3 619  9
6 GJB5 3 4 10 3 277 0 97 2 CAC G4 2 6 10−3 1.31   0 4
7 CLIC1 1 9 2 1.738 5 3 BRB1 3 −3 698
8 KCND3 0 10 1 0.487 0 4 4 JB  3 7 10 3 588 0 63
9 K1 8 6 10− 1 0 269 0 3 5 CACNB4 4 3 10−3 0 474  0 6
0 G IA1 8 7 1 0.1049 3 56 AC 1 5 − 62  0
1 VDAC1 .0  10−10 1.8 0 96 57 KCNK2 5 10 .51  0 4
2 GJB3 2.1 × 10−10 . 53  0.96 58 T P 1 5.4  10−  . 65  0.70 
3 KCNN2 .   -10 4 337 1 59 7 5 − .396 4
4  5.5 × 10−10 0 8 0 84 0 G IK1 6 3 10 1.885 0 72
5 IT R3 .1  −9 2.311  .  1 RIN2D 6.7  −  1.922  .  
16 RYR1 .8  9 0.2414  . 1 2 CLIC4 6.8  −  0.671  . 9 
17 GJA1 2.1  9 .086  .98 3 CA A S 7.7  −  1.91  . 7 
18 KCNJ13 1.    .266  . 6 4 CATSPER2 8.1  −3 0.677  . 5 
19 TRPV2 3 0 8 1 77 8 5 GABRP 8 1 3 0.3014 
0 GJB1 4 8 2 643 93 66 GJA4 9 0 3 0.5357  
1 CLIC3 4.0  8 .118  . 5 67 KCNJ15 9.0  3 .506  .64 
2 LRRC8B 4 4 8 459 0 68 CNGB3 0 0.63  9
3 HCN2 2.1  7 .88  .89 69 SCNN1D .0   0.735  .69 
4 TRPM1 3 0 −7 368 77 0 GRIA4 2 0 71 6
5 BEST2 3 6 −7 456 6 1 TRPM3 1 3 0 62 2
26 QP3 6 −7 067 97 2 CHRNA10 1 5 0.759 68
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.71 88 ASI 1 4.1 × 10−2 0.71
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Table 2. List of ion channels genes showing differ ntial expression in nev  vs. melanoma (p < 0.05), sorted according to the AUC value  The analysis was carried out in the 








AUC No. Gene ame 





1 NO  .7 × 10−18 0. 31  0. 8 47 2 1.5 × 10−3 0.4388  0.73 
2 CNK7 1.8 × 10−17 0.081  0.94 48 TRPV6 1.9 × 10−3 .576  0.65 
3 S N 1A 1.  × 10−14 0.07  0. 8 49 LIC2 2.0 × 10−3 0.3 9  0.87 
4 S NN1B 1.4 × 10 4 0.313  0.  0 SCN3A 2.2 × 10  .382  0.64 
5 G BRE 2.3 × 10−13 0.203  0. 5 1 G I 2A 2.3 × 10−3 0.619  0.69 
6 JB5 3.4 × 10−13 0.1277  0.97 52 CAC G4 2.6 × 10−3 .317  0. 4 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 BRB1 3.0 × 10  0.698  0.69 
8 K D3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7 × 10−3 .588  0. 3 
9 KCNK1 8.6 × 10−11 0.269  0. 3 55 CACNB4 4.3 × 10−3 0.474  0.66 
0 GRIA1 8.7 × 10−11 0.1049  0.93 56 CNA11 5.0 × 10  . 29  0.70 
1 VDAC1 2.   −10 1.8  .96 57 KCNK2 5.0  −3 0.512  . 4 
12 3 2.   −10 0.2453  . 6 58 TRPC1 5.4  −3 0.665  .70 
13 KCNN2 3.6  -10 4.337  .91 59 TRPC7 5.7   1.39   .7  
14 QP1 5.5  −10 .268  .84 0 GRIK1 6.3  −3 1.885  .72 
15 ITPR3 1.   −9 2.311  .93 1 GRI 2  6.7  −3 1.922  .75 
16 YR1 1.8  −9 0.2414  .81 62 CL C  6.8  −3 0.671  . 9 
17 GJA1 2.1  −9 .08  .98 63 CACNA1S 7.7  −3 1.91  . 7 
18 K NJ13 1.   −8 .2 6  .86 64 ATSPER2 8.1  −3 .677  .75 
19 TRPV2 3.0  −8 1. 7  .88 65 GABRP 8.1  −3 0.3014  .69 
0 GJB  3.4  −8 2. 43  .9  66 GJ 4 9.0  −3 0.5357  .6  
1 CLI 3 4.0  −8 .118  . 5 67 J15 9.   −3 0.506  .64 
22 LRRC8B 4.4  −8 .459  .90 68 CNGB3 1.   −2 0.63  .69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 QP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 S N1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
.6
43 LRRC8D 2.8 × 10−4 1.39
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1 KCNJ1  3.    .388  . 0 77 CHR 1 .1  −2 .75   . 8 
2 KCNJ18 3.5  6 0.388  .  78 ANO  2.4  −2 .67  . 8 
3 TRPM4 .6  −6 .1 4  . 7 79 CHRN 2 2.6  -2 1 383  .70 
4 S3 7.7  −6 . 0   .93 0 SCNN 2.8  -2 1.45  . 7 
5 PKD2L1 8.7  −6 2.66  .86 1 T PC6 2.8  -2 0.5 4  .  
36 P2RX4 .0  −5 6  . 5 2 CNA1 3.   −2 0 79  .67 
37 GRIK2 3.9  −5 3.92   .86 3 PKD2L2 3.   −2 0.44   .52 
38 K J4 .   −5 2.87  .84 4 G B A6 3 9  1 0.622  5
39 TRPM2 6 5 -5 0.219 93 5 RINB2 3 9 225
0 CLCN7 1 2 - 1.753 80 86 K NJ2 0 1.33 2
1 MCOLN3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 2 6 0.483 1 88 ASI 1 4.1 × 10−2 0.71 0.63 
43 LRR 8D 2.8 × 10−4 1. 9  0.78 89 AQP5 4.1 × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.78 89 AQP5 4.1 × 10−2 1.498
Cancers 2019, 11, x 7 of 22 
1 KCNJ12 3.5  −  0.388  . 0 77 CHRNB1 .   −2 .75   . 8 
2 K NJ18 3 5 −6 0 388 0 78 NO2 2 4 −2 67 8
3 TRPM4 6 −6 0 154 7 79 CHRNB2 2 6 -2 1 383 70
4 S3 7 7 10−6 0. 03 0 93 0 SCNN1G 2 8 - 1.45 7
5 KD2L1 8 7 −6 2.66 86 1 T PC6 2 8 - 0 594
36 P RX4 0 −5 6 5 2 A1 3 0 79 67
37 GRIK2 3.9  5 3.9  .86 3 PKD2L2 3.    0.447  .52 
38 K J4 5 0 5 2.87 84 4 G BRA6 3 9 0.622 5
39 TRPM2 6 5 -5 0.219 93 5 GRINB2 3 9 225
0 CLCN7 1 2 - 1.753 80 86 K NJ2 0 1.33 2
1 M OLN3 2 2 0.352 62 87 V5 0 1.29 6
2 SCN2B 2 6 0.483 1 88 ASIC1 4.1 × 10−2 0.71 0.63 
43 LRR 8D 2.8 × 10−4 3   0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CLCN6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.09   0.69 
46 C GA1 5.0 × 10−4 0.58  0.72       
  
0.67
44 M OLN1 3.8 × 10−4 1.43
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31 KCNJ12 3.  × 10−6 0.388  0.80 77 CHR 1 2.1 × 10−2 0.754  0.68 
32 K NJ18 3.5 × 10−6 0.388  0.  78 NO  2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.15   0.87 79 CHRN 2 2.  × 10-2 1.383  0.70 
34 K S3 7.7 × 10−6 0. 03  0.93 80 S NN1  2.8  10-2 1.45  0.67 
35 PKD2L1 8.7  −6 2.66  .86 1 TRP 6 2.   -2 0.5 4  .  
36 P2RX4 1.0  10−5 1.756  0.85 8  KCNA1 3.0  10−2 0.7   0.67 
37 GRIK2 3.9  10−5 3.9 2  0.86 83 PKD2L2 3.0  10−2 0.447  0.52 
38 KCNJ4 5.0  10−5 2.87  0.84 84 GAB A6 3.  × 10−2 0.622  0.65 
39 TRPM2 6.  × 10-5 0.219  0.93 85 RI B2 3.9 × 10−2 1.225  0.67 
40 CLCN7 1.  × 10-4 1.753  0.80 86 K J2 4.0 × 10−2 1.33  0.72 
41 MCOLN3 2.2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0.483  0.71 88 A I 1 4.  × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1.39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOL 1 3.8 × 10−4 1.43  0.72 90 CA G3 4.3 × 10−2 1.903  0.73 
45 CL 6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.09   0.69 
46 CN A1 5.0 × 10−4 0.58  0.72       
  
0.72 90 CAC G3 4.3 × 10−2 1.9 3
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1 KCNJ 2 .   −6 0.388  . 0 77 CHR B1 .1  −2 .75   . 8 
2 KCNJ18 3.5  6 0.388  . 0 78 ANO2 2.4   .67  . 8 
3 TRPM4 .6  6 0.15  . 7 79 CHRN 2 2.   -  1.383  .70 
4 NS3 .7  −6 0.403  .93 0 S NN1G 2.8  -2 1.45  . 7 
5 KD2L1 8.7  −6 2.66  .86 1 T PC6 2.   -  0.594  .  
36 P2 X4 .0  −5 . 6  . 5 2 A1 3.    0.79  .67 
37 GRIK2 3.9  −5 3.9  .86 3 PKD2L2 3.   −2 0.447  .52 
38 K J4 5.0  5 2.87  .84 4 G B A6 3.    0.622  . 5 
39 TRPM  6.   -5 0.21  .93 5 RI B2 3.9   .225  .  
0 CL N7 1.   -4 1.753  .80 86 K J2 .0  −2 1.33  . 2 
1 MCOLN3 .2   0.352  .62 87 V5 .0   1.29  . 6 
2 SCN2B 2.6  −4 0.483  . 1 88 ASIC1 4.  × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 39  0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL 6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2.097  0.69 
46 GA1 5.0 × 10−4 0.58  0.72       
  
.73
45 CLCN6 5.0 × 10−4 0.7
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 NO1 8.7  −18 .231  . 8 47 2 .   −3 0.4388  .73 
2 K7 .8  −17 0.081  . 4 48 TRPV6 .   −3 0.576  .6  
3 S NN A .  × 10−14 0.07  .98 49 CLI 2 2.0  −3 0.319  .87 
4 S NN1B 1.4 × −14 .31   .96 50 S 3A .2  −3 0.3 2  . 4 
5 GABRE 2.3 × −13 . 03  .95 51 GRI 2A .   −3 .619  .69 
6 GJB5 3.4  −13 . 277  . 7 2 C C G4 2.6  −3 1.317  . 4 
7 CLIC1 1.9 × −12 1.738  . 5 3 ABRB1 3.0  −3 0.698  .69 
8 KCND3 .0  −11 0.487  . 4 4 GJB4 3.7  −3 0.588  .63 
9 K1 8.6 × 10−11 .269  .93 5 CACNB4 4.3  −3 0.474  .66 
10 GRIA1 8.7  −11 0.1049  .93 56 C C A11 5.0 × −3 0.629  . 0 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KC K2 5.0 × 10−3 0.51   0.64 
2 J 3 2.1 × 10−10 . 53  0.96 58 TRP 1 5.4 × 10−3 . 65  0.70 
3 KCNN2 3.6 × 10-10 4.337  0. 1 59 TRP 7 5.  × 10−3 1.396  0.74 
4 AQP  5.5 × 10−10 0. 8  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
5 IT R3 1.1 × 10−9 2.311  0.93 61 RI 2  6.7 × 10−3 1.922  0.75 
16 YR  1.8 × 10−9 0.2414  0.81 2 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 3 CA 1S 7.7 × 10−3 1.91  0.77 
18 KCNJ13 1.9 × 10−8 0.266  0.86 4 ATSPE 2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0. 8 5 GABRP 8.1 × 10−3 0.3014  0.  
20 GJB1 .4 × 10−8 2.643  0.93 66 GJ 4 9.0 × 10−3 0.5357  0. 8 
21 CLI 3 4.0 × 10−8 0.118  0.85 67 J15 9.0 × 10−3 .506  0.64 
2 LRRC8B 4.4 × 10−8 0.459  0. 0 68 CNGB3 .0 × 10−2 0.63  0. 9 
3 HCN2 2.1  −7 .88  .89 69 SCNN1D .0  −2 0.735  .69 
4 TRPM1 3.0  −7 .368  .77 0 GRIA4 .2  −2 0.71  .6  
5 BEST2 3.6  −7 .456  . 6 1 TRPM3 1.3  −2 0. 62  . 2 
26 QP3 6.   −7 .067  .97 2 CHRN 10 1.5  −2 0.759  .68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.7 91 TRPC4 4.3 × 10−2 2. 97
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31 KCNJ 2 .  × 10−6 0.388  0.80 77 CHR 1 2.  × 10−2 0.754  0.68 
32 KCNJ18 3.5 × 10−6 0.388  0.80 78 ANO2 2.4 × 10−2 0.67  0.68 
33 TRPM4 3.6 × 10−6 0.15   0.87 79 CHRN 2 2.  × 10-2 1.383  0.70 
34 K S3 .7 × 10−6 0.403  0.93 80 S NN1G 2.8 × 10-2 1.45  0.67 
35 PKD2L1 8.7 × 10−6 2.66  0.86 81 TRP 6 2.  × 10-2 0.594  0.67 
36 P2 X4 .0 × 10−5 1.756  0.85 82 KCNA1 3.0 × 10−2 0.79  0.67 
37 GRIK2 3.9 × 10−5 3.9 2  0.86 83 PKD2L2 3.0 × 10−2 0.447  0.52 
38 KCNJ4 5.0 × 10−5 2.87  0.84 84 GAB A6 3.  × 10−2 0.622  0.65 
39 TRPM  6.  × 10-5 0.2 9  0.93 85 GRI B2 3.9 × 10−2 1.225  0.67 
40 CL 7 1.  × 10-4 1.753  0.80 86 K J2 4.0 × 10−2 1.33  0.72 
41 MCOLN3 .2 × 10−4 0.352  0.62 87 TRPV5 4.0 × 10−2 1.29  0.66 
42 SCN2B 2.6 × 10−4 0. 83  0.71 88 ASI 1 4.  × 10−2 0.71  0.63 
43 LRR 8D 2.8 × 10−4 1 3   0.78 89 AQP5 4.  × 10−2 1.498  0.67 
44 MCOLN1 3.8 × 10−4 1.43  0.72 90 CACNG3 4.3 × 10−2 1.903  0.73 
45 CL 6 5.0 × 10−4 0.74  0.79 91 TRPC4 4.3 × 10−2 2. 97  0.69 
46 A1 5.0 × 10−4 0.58  0.72       
  
.69
46 CNGA1 5.0 × 10−4 0.58
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Table 2. List of ion channels genes showing differential expression in nevi vs. melanoma (p < 0.05), sorted according to the AUC value. The analysis was carried out in the 








AUC No. Gene ame 





1 ANO1 8.7  −18 .231  . 8 47 CACNB2 .5  −3 0.4388  .73 
2 KC K7 1.8  10−17 0.081  0.94 48 TRPV6 1.9  10−3 0.576  0.65 
3 SCNN1A 1.   −14 0.07  .98 49 CLIC2 2.0  −3 0.319  .87 
4 S NN1B 1.4  10−14 0.313  0.96 50 S 3A 2.2  10−3 0.382  0.64 
5 GABRE 2.3  10−13 0.203  0.95 51 GRI 2A 2.3  10−3 0.619  0.69 
6 GJB5 3.4  −13 0.1277  . 7 52 C C G4 2.6  −3 1.317  . 4 
7 CLIC1 1.9 × 10−12 1.738  0.95 53 GABRB1 3.0  10−3 0.698  0.69 
8 KCND3 2.0 × 10−11 0.487  0.94 54 GJB4 3.7  10−3 0.588  0.63 
9 KCNK1 8.6 × 10−11 .269  .93 55 CACNB4 4.3  −3 0.474  .66 
10 GRIA1 8.7 × 10−11 0.1049  0.93 56 CAC A11 5.0 × 10−3 0.629  0.70 
11 VDAC1 2.0 × 10−10 1.8  0.96 57 KCNK2 5.0 × 10−3 0.512  0.64 
12 GJB3 2.1 × 10−10 0.2453  0.96 58 TRPC1 5.4 × 10−3 0.665  0.70 
13 KCNN2 3.6 × 10-10 4.337  0.91 59 TRP 7 5.7 × 10−3 1.396  0.74 
14 AQP1 5.5 × 10−10 0.268  0.84 60 GRIK1 6.3 × 10−3 1.885  0.72 
15 ITPR3 1.1 × 10−9 2.311  0.93 61 GRIN2D 6.7 × 10−3 1.922  0.75 
16 RYR1 1.8 × 10−9 0.2414  0.81 62 CLIC4 6.8 × 10−3 0.671  0.69 
17 GJA1 2.1 × 10−9 0.086  0.98 63 CACN 1S 7.7 × 10−3 1.91  0.77 
18 KC J13 1.9 × 10−8 0.266  0.86 64 CATSPER2 8.1 × 10−3 0.677  0.75 
19 TRPV2 3.0 × 10−8 1.77  0.88 65 GABRP 8.1 × 10−3 0.3014  0.69 
20 GJB1 3.4 × 10−8 2.643  0.93 66 GJA4 9.0 × 10−3 0.5357  0.68 
21 CLIC3 4.0 × 10−8 0.118  0.85 67 KCNJ15 9.0 × 10−3 0.506  0.64 
22 LRRC8B 4.4 × 10−8 0.459  0.90 68 CNGB3 1.0 × 10−2 0.63  0.69 
23 HCN2 2.1 × 10−7 3.88  0.89 69 SCNN1D 1.0 × 10−2 0.735  0.69 
24 TRPM1 3.0 × 10−7 0.368  0.77 70 GRIA4 1.2 × 10−2 0.71  0.68 
25 BEST2 3.6 × 10−7 0.456  0.86 71 TRPM3 1.3 × 10−2 0.762  0.72 
26 AQP3 6.9 × 10−7 0.067  0.97 72 CHRNA10 1.5 × 10−2 0.759  0.68 
27 KCNN4 1.5 × 10−6 3.79  0.93 73 AQP9 1.9 × 10−2 0.56  0.75 
28 SCN1B 1.5 × 10-6 0.657  0.83 74 VDAC3 1.9 × 10−2 1.27  0.78 
29 LRRC8E 1.5 × 10-6 0.563  0.82 75 KCNV1 2.0 × 10−2 1.737  0.70 
30 CACNB1 2.9 × 10-6 0.614  0.82 76 VDAC2 2.0 × 10−2 1.15  0.71 
0.72
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Table 3. Ion channels genes showing very high discriminating ability (AUC > 0.90) in the Talantov dataset were validated in a first round validation in the Raskin
dataset. Genes passing the first validation were then validated in the Riker dataset. Genes passing screening phase and all two validations were searched in Pubmed
to identify those never directly related to melanoma. Genes showing 0 value in the “Novelty” column are genes never related to melanoma according to Pubmed
abstract. Five genes were selected according to this procedure (SCNN1A, GJB3, KCNK7, GJB1, KCNN2). Empty cells indicate lack of validation.
No. Gene Name
Screening Phase (in the Talantov Dataset,
GEO, GDS1375)
First-Round Validation
(in the Raskin Dataset,
GEO GSE15605) *
Second-Round


















1 SCNN1A 1.0 × 10−14 0.07 0.98 Yes (0.85) Yes (−4.94) 0
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Genes passing the first validation were then validated in the Riker dataset. Genes passing screening phase and all two validations were searched in Pubmed to identify 
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Screening Phase (in the Talantov Dataset, 
GEO, GDS1375) 
First-round Validation (in 
the Raskin Dataset, GEO 
GSE15605) * 
Second-Round 
Validation (in the Riker 
Dataset, Oncomine) ** 
Novelty (in PubMeds 
Abstracts) *** 
Full in Silico 
Validation 
63 Patients 62 Patients 59 Patients   
t Test 
Melanoma vs. Nevi 
Ratio Melan. 
vs. Nevi 
AUC Validation on AUC Value * 
Validation on Ratio 
Value 
Gene N me and Melanoma 
Words Co-Occurrence 
 
1 SCNN1A .0 × 10−14 .07 0.98 Yes (0.85) Yes (−4.94) 0  
2 ANO1 8.6 × 10−18 0.231 0.98 Yes (0.87)    
3 GJA1 2.1 × 10−9 0.086 0.98 Yes (0.88)    
4 GJB5 3.4 × 10−13 0.1277 0.97     
5 GJB3 2.1 × 10−10 0.2453 0.96 Yes (0.86) Yes (−6.662) 0  
6 AQP3 6.9 × 10−7 0.067 0.97     
7 SCNN1B 1.4 × 10−14 0.313 0.96 Yes (0.87)    
8 VDAC1 2.0 × 10−10 1.8 0.96     
9 CLIC1 1.9 × 10−12 1.738 0.96     
10 GABRE 2.3 × 10−13 0.203 0.95 Yes (0.88) Yes (−3.162) ≥1  
11 KCNK7 1.8 × 10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0  
12 KCND3 2.0 × 10−11 0.487 0.94 Yes (0.89)    
14 KCNN4 1.5 × 10−6 3.79 0.93     
13 ITPR3 1.1 × 10−9 2.311 0.93     
15 KCNK1 8.6 × 10−11 0.269 0.93 Yes (0.89)    
16 KCNS3 7.7 × 10−6 0.403 0.93     
17 TRPM2 6.5 × 10−5 0.219 0.93     
18 GRIA1 8.7 × 10−11 0.1049 0.93     
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0  
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0  
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of 
melanoma vs. normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was 
assessed onto the five genes validated in the first and second validations steps.
2 ANO1 8.6 × 10−18 0.231 0.98 Yes (0.87)
3 GJA1 2.1 × 10−9 0.086 0.98 Yes (0.88)
4 GJB5 3.4 × 10−13 0.1277 0.97
5 GJB3 2.1 × 10−10 0.2453 0.96 Yes (0.86) Yes (−6.662) 0
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Screening Phase (in the Talantov Dataset, 
GEO, GDS1375) 
First-round Validation (in 
the Raskin Dataset, GEO 
GSE15605) * 
Second-Round 
Validation (in the Riker 
Dataset, Oncomine) ** 
Novelty (in PubMeds 
Abstracts) *** 
Full in Silico 
Validation 
63 Patients 62 Patients 59 Patients   
t Test 
Melanoma vs. Nevi 
Ratio Melan. 
vs. Nevi 
AUC Validation on AUC Value * 
Validation on Ratio 
Value 
Gene Name and Melanoma 
Words Co-Occurrence 
 
1 SCNN1A .0  −14 0.07 . 8 Yes (0.85)  4.94) 0  
2 A O1 8.6  10−18 0.231 0.98 es (0.87)    
3 GJ 1 .1  −9 0.0 6 . 8 Yes (0.88)    
4 GJB5 3.4  −13 0.1277 . 7     
5 GJ 3 2.1  10−10 0.2453 0.96 es (0.86) es (−6.662) 0  
6 AQP3 6.9  −7 . 67 . 7     
7 SCNN1B 1.4  −14 .313 . 6 es ( . 7)    
8 VDAC1 2.0  10−10 1.8 0.96     
9 CLIC1 .9  −12 1.738 . 6     
0 GABRE 2.3  −13 . 03 . 5 es ( . 8) Yes (−3.162) ≥1  
11 K7 1.8  10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0  
2 KCND3 2.0  −11 .487 . 4 Yes (0.89)    
4 KCNN4 1.5  −6 3.79 .      
3 ITPR3 1.1  −9 .311 .      
15 K1 8.   −11 0.269 . 3 s ( .89)    
16 KCNS3 7.7 × 10−6 0.403 0.93     
17 TRPM2 6.5 × 10−5 0.219 0.93     
18 GRIA1 8.7 × 10−11 0.1049 0.93     
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0  
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0  
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of 
melanoma vs. normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was 
assessed onto the five genes validated in the first and second validations steps.
6 AQP3 6.9 × 10−7 0.067 0.97
7 SCNN1B 1.4 × 10−14 0.313 0.96 Yes (0.87)
8 VDAC1 2.0 × 10−10 1.8 0.96
9 CLIC1 1.9 × 10−12 1.738 0.96
10 GABRE 2.3 × 10−13 0.203 0.95 Yes (0.88) Yes (−3.162) ≥1
11 KCNK7 1.8 × 10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0
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Table 3. Ion channels genes showing very high discriminating ability (AUC > 0.90) in the Talantov dataset were validated in a first round validation in the Raskin dataset. 
Genes passing the first validation were then validated in the Riker dataset. Genes passing screening phase and all two validations were searched in Pubmed to identify 
those never directly related to melanoma. Genes showing 0 value in the “Novelty” column are genes never related to melanoma according to Pubmed abstract. Five genes 




Screening Phase (in the Talantov Dataset, 
GEO, GDS1375) 
First-round Validation (in 
the Raskin Dataset, GEO 
GSE15605) * 
Second-Round 
Validation (in the Riker 
Dataset, Oncomine) ** 
Novelty (in PubMeds 
Abstracts) *** 
Full in Silico 
Validation 
63 Patients 62 Patients 59 Patients  
t Test 
Melanoma vs. Nevi 
Ratio Melan. 
vs. Nevi 
AUC Validation on AUC Value * 
Validation on Ratio 
Value 
Gene Name and Melanoma 
Words Co-Occurrence 
 
1 SCNN1A .0 × 10−14 0.07 0.98 Yes (0.85)  4.94) 0  
2 ANO1 8.6 × 10−18 0.231 0.98 Yes (0.87)    
3 GJA1 2.1 × 10−9 0.086 0.98 Yes (0.88)    
4 GJB5 3.4 × 10−13 0.1277 0.97     
5 GJB3 2.1 × 10−10 0.2453 0.96 Yes (0.86) Yes (−6.662) 0  
6 AQP3 6.9 × 10−7 0.067 0.97     
7 SCNN1B 1.4 × 10−14 0.313 0.96 Yes (0.87)    
8 VDAC1 2.0 × 10−10 1.8 0.96     
9 CLIC1 1.9 × 10−12 1.738 0.96     
10 GABRE 2.3 × 10−13 0.203 0.95 Yes (0.88) Yes (−3.162) ≥1  
11 KCNK7 1.8 × 10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0  
12 KCND3 2.0 × 10−11 0.487 0.94 Yes (0.89)    
14 KCNN4 1.5 × 10−6 3.79 0.93     
13 ITPR3 1.1 × 10−9 2.311 0.93     
15 KCNK1 8.6 × 10−11 0.269 0.93 Yes (0.89)    
16 KCNS3 7.7 × 10−6 0.403 0.93     
17 TRPM2 6.5 × 10−5 0.219 0.93     
18 GRIA1 8.7 × 10−11 0.1049 0.93     
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0  
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0  
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of 
melanoma vs. normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was 
assessed onto the five genes validated in the first and second validations steps.
12 KCND3 2.0 × 10−11 0.487 0.94 Yes (0.89)
14 KCNN4 1.5 × 10−6 3.79 0.93
13 ITPR3 1.1 × 10−9 2.311 0.93
15 KCNK1 8.6 × 10−11 0. 69 0.93 Yes (0.89)
16 KCNS3 7.7 × 10−6 0.403 0.93
17 TRPM2 6.5 × 10−5 0.219 0.93
18 GRIA1 8.7 × 10−11 0.1049 0.93
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0
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Table 3. Ion channels genes showing very high discriminating ability (AUC > 0.90) in the Talantov dataset were validated in a first round validation in the Raskin dataset. 
Genes passing the first validation were then validated in the Riker dataset. Genes passing screening phase and all two validations were searched in Pubmed to identify 
those never directly related to melanoma. Genes showing 0 value in the “Novelty” column are genes never related to melanoma according to Pubmed abstract. Five genes 




Screening Phase (in the Talantov Dataset, 
GEO, GDS1375) 
First-round Validation (in 
the Raskin Dataset, GEO 
GSE15605 * 
Second-Round 
Validation (in the Riker 
Dataset, Oncomine) ** 
Novelty (in PubMeds 
Abstracts) *** 
Full in Silico 
Validation 
63 Patients 62 Patients 59 Patients  
t Test 
Melanoma vs. Nevi 
Ratio Melan. 
vs. Nevi 
AUC Validation on AUC Value * 
Valid tion on Rat o 
Value 
Gene Name and Mela oma 
Words Co-Occurrence 
 
1 SCNN1A 1.   −14 0.07 . 8  ( . 5)  (−4.94)   
2 ANO1 8.   −18 0.2 1 . 8  ( .87)    
3 GJA1 2.1 × 10−9 0.086 0.98 Yes (0.88)    
4 GJB5 3.4 × 10−13 0.1277 0.97    
5 GJB3 2.1 × 10−10 0.2453 0.96 Yes (0.86) Yes (−6.662) 0  
6 AQP3 6.9 × 10−7 0.067 0.97    
7 SCNN1B 1.4 × 10−14 0.313 0.96 Yes (0.87)    
8 VDAC1 2.0 × 10−10 1.8 0.96     
9 CLIC1 1.9 × 10−12 1.738 0.96     
10 GABRE 2.3 × 10−13 0.203 0.95 Yes (0.88) Yes (−3.162) ≥1  
11 KCNK7 1.8 × 10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0  
12 KCND3 2.0 × 10−11 0.487 0.94 Yes (0.89)    
14 KCNN4 1.5 × 10−6 3.79 0.93     
13 ITPR3 1.1 × 10−9 2.311 0.93     
15 KCNK1 8.6 × 10−11 0.269 0.93 Yes (0.89)    
16 KCNS3 7.7 × 10−6 0.403 0.93     
17 TRPM2 6.5 × 10−5 0.219 0.93     
18 GRIA1 8.7 × 10−11 0.1049 0.93     
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0  
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0  
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of 
melanoma vs. normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was 
assessed onto the five genes validated in the first and second validations steps.
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0
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Genes passing the first validation were then validated in the Riker dataset. Genes passing screening phase and all two validations were searched in Pubmed to identify 
those never directly related to melanoma. Genes showing 0 value in the “Novelty” column are genes never related to melanoma according to Pubmed abstract. Five genes 




Screening Phase (in the Talantov Dataset, 
GEO, GDS1375) 
First-round Validation (in 
the Raskin Dataset, GEO 
GSE15605) * 
Second-Round 
Validation (in the Riker 
Dataset, Oncomine) ** 
Novelty (in PubMeds 
Abstracts) *** 
Full in Silico 
Validation 
63 Patients 62 Patients 59 Patients   
t Test 
Melanoma vs. Nevi 
Ratio Melan. 
vs. Nevi 
AUC Validation on AUC Value * 
Validation on Ratio 
Value 
Gene Name and Melanoma 
Words Co-Occurrence 
1 SCNN1A .0 × 10−14 0.07 0.98 Yes (0.85) Yes (−4.94) 0  
2 ANO1 8.6 × 10−18 0.231 0.98 Yes (0.87)    
3 GJA1 2.1 × 10−9 0.086 0.98 Yes (0.88)    
4 GJB5 3.4 × 10−13 0.1277 0.97     
5 GJB3 2.1 × 10−10 0.2453 0.96 Yes (0.86) Yes (−6.662) 0  
6 AQP3 6.9 × 10−7 0.067 0.97     
7 SCNN1B 1.4 × 10−14 0.313 0.96 Yes (0.87)    
8 VDAC1 2.0 × 10−10 1.8 0.96     
9 CLIC1 1.9 × 10−12 1.738 0.96     
10 GABRE 2.3 × 10−13 0.203 0.95 Yes (0.88) Yes (−3.162) ≥1  
11 KCNK7 1.8 × 10−17 0.081 0.94 Yes (0.86) Yes (−2.832) 0  
12 KCND3 2.0 × 10−11 0.487 0.94 Yes (0.89)    
14 KCNN4 1.5 × 10−6 3.79 0.93     
13 ITPR3 1.1 × 10−9 2.311 0.93     
15 KCNK1 8.6 × 10−11 0.269 0.93 Yes (0.89)    
16 KCNS3 7.7 × 10−6 0.403 0.93     
17 TRPM2 6.5 × 10−5 0.219 0.93     
18 GRIA1 8.7 × 10−11 0.1049 0.93     
19 GJB1 3.4 × 10−8 2.643 0.93 Yes (0.87) Yes (3.303) 0  
20 KCNN2 3.6 × 10−10 4.337 0.91 Yes (0.91) Yes (2.284) 0  
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of 
melanoma vs. normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was 
assessed onto the five genes validated in the first and second validations steps.
* validation in GSE15605 was considered effective if AUC > 0.85 (AUC is reported in parenthesis); ** validation in Riker dataset was considered effective if difference of melanoma vs.
normal skin is <0.5 or >1.5 (difference is reported in parenthesis, calculated from log2 median-centered intensity according to Oncomine); *** Novelty was assessed onto the five genes
validated in the first and second validations steps.
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No co-occurrence of their gene name or synonymous names is reported with “melanoma” word, 
in any field in PubMed searches (see Table 3, right end-side column). These five genes were then 
selected as the best novel candidates as melanoma markers and melanoma molecular targets. Figure 
2 depicts the corresponding ROC curves of the five best candidates computed on the expression 
values reported in the GDS 1375 dataset. In all cases an AUC > 0.90 and p < 0.0001 is reported, i.e., a 
very high and significant ability to discriminate melanoma from healthy controls samples. The 
sensitivity and specificity values were computed as reported in the Methods section, indicating: 92% 
specificity and 97.7% sensitivity for SCNN1A; 96% specificity and 91% sensitivity for GJB3; 84% 
specificity and 97.7 sensitivity for KCNK7; 96% specificity and 84.4% sensitivity for GJB1; 100% 
specificity and 82.2% sensitivity for KCNN2. 
 
 
Figure 2. ROC analysis of the five genes expression showing a very high ability to discriminate 
controls from melanoma samples, validated in two samples datasets. These genes also show a strong 
expression ratio in the third dataset and are not reported to be related to melanoma according to 
PubMed searches. ROC analysis evaluates how the given measure (gene-expression level in this case) 
relates to sensitivity (ability to detect melanoma presence) and specificity (ability to detect melanoma 
absence). AUC (area under curve) of SCNN1A, GJB3, KCNK7, GJB1, and KCNN2 indicate very high 
ability of their expression levels to discriminate melanoma from controls, namely 98%, 96%, 94%, 93%, 
and 91%, respectively. 
2.2. Experimental Validation 
According to the in silico screening and validations steps carried out and described above, 
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2.2. Experimental Validation
According to the in silico screening and validations steps carried out and described above,
SCNN1A, GJB3, KCNK7, GJB1, KCNN2 genes were selected as best candidate melanoma markers
and potential molecular targets. The five identified genes are down-regulated in three cases (namely
SCNN1A, GJB3, KCNK7) and up-regulated in two cases (namely GJB1 and KCNN2). Interestingly,
both down- and up-regulated molecules may represent suitable molecular targets, exploiting the
available blockers or activators, respectively. The five genes were then analyzed as targets of known
FDA-approved drugs. The analysis was carried out on http://www.dgidb.org/search_interactions.
Table 4 reports the results of this analysis, indicating a number of drugs (namely triamterene, amiloride,
flufenamic acid, carbenoxolone, miconazole, tubucurarine, and bendroflumethiazide) known to
target the identified ion channels. Main known tissue targets and pharmacological actions are
also reported; such drugs act on muscles, joints, kidney, CNS, and also act on systemic targets.
We focused our attention onto miconazole, an antifungal compound commonly used to treat skin
infections. Miconazole has known skin distribution and dermatological pharmacokinetics; we,
therefore, hypothesized it may be suitable for other skin diseases.
A Chilibot analysis identifies literature-reported functional relationships within user-defined
terms. It identified the known functional relationships reported in literature among melanoma, ion
channels, miconazole and cytochrome P450, one of the best characterized targets of miconazole.
Chilibot analysis is reported in Figure 3, highlighting that miconazole inhibits cytochrome P450;
Cancers 2019, 11, 446 10 of 22
melanoma and cytochrome P450 are connected by both stimulatory and inhibitory relations; potassium
channels are known to inhibit cytochrome P450 [28] and their inhibitors are known to inhibit
melanoma [29]. According to this scenario, a potassium channel inhibitor and cytochrome P450
inhibitor such as miconazole may significantly affect melanoma proliferation. Miconazole was then
tested in vitro in a proliferation assay on two human melanoma cell lines, i.e., one more aggressive
(namely A-375) and the other less aggressive (namely SKMEL-28). Proliferation was measured in the
presence of 10% FCS. The results of a dose-dependent and time-dependent proliferation assay are
reported in Figure 4A,B. Miconazole 10, 30, and 50 µM doses show a strong dose-dependent inhibition
of serum-induced proliferation. Figure 4C shows that miconazole does not have any inhibitory effect
on keratinocytes ad fibroblast control cells. Figure 5 reports the number of dead cells in the presence
of 10% serum, indicating 30 and 50 µM as more potent cell-death inducers both in A-375 and in
SKMEL-28 cells.
We, therefore, investigated whether the anti-proliferation effect of miconazole may be affected
by specifically modulating KCNN2 expression. Figure 6 reports the strong increase of miconazole
anti-proliferation effect upon KCNN2 siRNA silencing (Figure 6A). Western blot analysis and
densitometry quantification is reported in Figure 6B and confirms the strong downregulation of
KCNN2 achieved by siRNA treatment. Since the molecular form of miconazole used in the present
study is miconazole-nitrate, as control the effect of ammonium-nitrate was also evaluated. Figure 6C
shows that nitrate, at the same doses used for miconazole, does not show any significant effect.
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Table 4. Gene-drug interaction according to the Drug Gene Interaction Database (www.dgidb.org). The five genes selected in Table 3 are investigated. Drugs known to
target the given genes and interaction type are according to www.dgidb.org. Main target tissues, pharmacological action and IUPAC (International Union of Pure
and Applied Chemistry) are derived from Drugbank (https://www.drugbank.ca/drugs). EC50 of the indicated pharmacological actions are also reported with
corresponding reference. References indicating the ion channel/drug interaction are reported.
Gene Name Drug Targeting the Gene, According towww.dgidb.org, and IUPAC Name Reference (PMID)
Interaction Type
with the Gene Main Target Tissue Action and Indications EC50
SCNN1A
Triamterene




[32] channel blocker kidney diuretic; congestive heartfailure; hypertension. 0.1 µM [33]
GJB3
Flufenamic acid




















[34] channel blocker CNS
diagnostic in myastenia






[34] channel blocker kidney smoothmuscle cells
Anti HBV, diuretic;
anti-edema; hypertension 53 µM [41]
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2.3. Mechanisms Underlying Miconazole Action
Miconazole is reported to primarily target 14-α demethylase, a cytochrome P-450 enzyme
involved in conversion of lanos erol to e gos e ol, an essential component of the fungal cell membrane
(see Drug Ba k at https://www.drugbank.ca/drugs/DB01110). Nevertheless, it also inhibits several
other targets, including endothelial nitric oxi e synthase and inducible nitric oxide synthase as
well as several potassium channels, namely: calcium-activated potassium channel subunit alpha-1,
calcium-activated potassium channel subunit beta-1, calcium-activated potassium channel subunit
beta-2, calcium-activated potassium channel subunit beta-3, calcium-activated potassium channel
subunit beta-4, intermediate conductance calcium-activated potassium channel protein 4, small
conductance calcium-activated potassium channel protein 1, small conductance calcium-activated
potassium channel protein 2, small conductance calcium-activated potassium channel protein 3,
potassium voltage-gated channel subfamily H member 2, potassium voltage-gated channel subfamily
H member 6, and potassium voltage-gated channel subfamily H member 7. It is also a partial agonist
of nuclear receptor subfamily 1 group I member 2. According to a STRING analysis carried out at
www.string-db.org, such proteins are strongly involved in arginine metabolism, potassium transport,
control of guanylate cyclase, nitric oxide synthesis, blood circulation and synaptic transmission. Table 5
highlights the top 10 biological processes enriched in a statistically significant way by analyzing the
above reported proteins, known miconazole targets.
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Table 5. Top 10 biological processes enriched in a statistically significant way by investigating in a
STRING “multiple proteins” search the following molecules: CYP51A1, NOS3, NOS2, NOS1, KCNMA1,
KCNMB3, KCNN4, KCNH2, KCNH7, KCNH6, KCNN2.
Biological Process Pathway ID False Discovery Rate
Potassium ion transmembrane transport GO:00781805 1.9 × 10−7
Arginine catabolic process GO:0006527 6.4 × 10−6
Synaptic transmission GO:0007268 6.4 × 10−6
Positive regulation of guanylate cyclase activity GO:0031284 4.2 × 10−5
Regulation of system process CO:0044057 4.2 × 10−5
Nitric oxide biosynthetic process GO:0006809 5.3 × 10−5
Regulation of potassium ion transport GO:0043266 5.7 × 10−5
Regulation of blood circulation GO:1903522 5.7 × 10−5
Nitric oxide mediated signal transduction GO:0007263 8.1 × 10−5
Blood circulation GO:0008015 8.3 × 10−5
3. Discussion
Ion channels have been shown to play a role in melanoma biology [42]. The number of studies
relating ion channels to melanoma has increased in the last few years and ion channels are now
recognized as potential co-targets in the new melanoma therapeutic strategies currently under
continuous development [43]. We have previously reported strong and significant expression changes
of several ion channels in solid tumors including glioblastoma, breast cancer, lung cancer, bladder
cancer, and melanoma [19] and also proposed a possible role of ion channels in brain metastases
onset [44]. Figure 3 of the present study also underlines that several studies identify reciprocal
stimulatory relationships of melanoma and ion channels. The present study presents for the first time
an extensive analysis of ion channels expression in human melanoma biopsies indicating a number
of potential highly effective markers accurately validated in silico and never previously related to
melanoma. An in silico procedure (summarized in Figure 1), after an initial screening on a first human
biopsies dataset, progressively leads to the selection of five genes in a double-validation step carried
out in two more human melanoma-patients datasets. The five ion channels selected as best candidates
and never previously directly related to melanoma (namely SCNN1A, GJB3, KCNK7, GJB1, KCNN2)
show very high AUC values (>0.90 in all cases) and very high specificity and sensitivity values (>90%
in most cases). In a few cases these genes have been related to other cancers such as lung cancer [45],
breast cancer [46], thyroid cancer [47], and ovarian cancer [48]. On the other hand, mir125B, which is
known to target the SCNN1A gene [49] has been reported to control melanoma progression [50].
We have previously published a study involving a pure in silico four-step validation procedure
carried out on autophagy-related genes in more than 500 melanoma patients [51]. In that study
we demonstrated that many autophagy-related genes undergo relevant and significant expression
changes in melanoma biopsies as compared to controls, and three genes, namely WIP1, PEX3 and
BAG1, show impressive melanoma markers features, such as very high AUC values and sensibility
and specificity values. Interestingly enough, ion channels recently emerged as key regulators of
autophagy [52], further extending their potential clinical applications. We, therefore, underline here
that ion channels may represent suitable molecular targets for novel therapeutic/diagnostic approaches
in the melanoma field. The current study investigates this hypothesis. By analyzing ion channels
expression in 170 human melanoma biopsies, we show that an accurate preliminary in silico validation
is able to identify candidates as relevant markers or molecular targets (see Table 3). A number
of drugs, commonly used in clinics in different pathological conditions, are known to target the 5
best candidates identified. This allowed us to hypothesize novel potential clinical applications in a
melanoma set up, for the drugs indicated in Table 3, within a drug repositioning strategy. Although
all drugs listed in Table 4 may be potentially effective, we focused our attention on miconazole,
given its known skin-targeting properties [53]. Miconazole is a known cytochrome P-450 inhibitor
targeting ion channels including KCNN2 [38,54]. In the clinical practice it is commonly used as an
antifungal topic compound in skin infections or for systemic infections, and, within the drugs reported
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in Table 3, sounds as the best candidate for skin-related lesions or systemic lesions of skin origin such
as melanoma. Further, miconazole targets the KCNN2 gene; this gene appears to be the best candidate
among the five identified in Table 3, being the only one with AUC > 0.90 in both screening phase and
first validation phase, and with very high melanoma vs. ctrl expression ratios (see Table 3). Figure 4
of the present study demonstrates that miconazole strongly reduces (up to 90%) the serum-induced
proliferation of A-375 (more-aggressive) and SKMEL-28 (less-aggressive) melanoma cells [55]. A375
and SK-MEL-28 cells are largely studied human melanoma cells for their different aggressiveness
and malignancy. We have recently correlated their aggressive phenotype with different molecular
profiles [56]. In both cell types high levels of p53 have been demonstrated [57], while A-375 express
higher Bax level [58]. Figure 4 also shows that the anti-proliferation effect of miconazole appears to be
specific for melanoma cells, since proliferation of ctrl cells (keratinocytes and fibroblasts) is not affected.
All together such data suggest a possible topical application of miconazole in the skin treatment of the
excised primary melanoma.
Figure 5 shows that miconazole also induces a strong cell-death, possibly suggesting
adjuvant applications in metastatic stages. Miconazole has been previously shown to have
some anti-proliferative effect in mouse melanoma cells (about 50% inhibitory action) and a mild
anti-melanogenesis effect [59], while we show for the first time a much stronger activity both as
anti-proliferation and as cell-death inducer in human cells lines, particularly in A-375 cells, known to
have an aggressive phenotype. Antitumor effects of miconazole have been previously reported
in cancers setup different than melanoma [60–63], while the present study represents the first
evidence indicating miconazole strong anti-proliferative and death-inducing activity in melanoma cells.
Interestingly, we demonstrate in the present study that the KCNN2 ion channel strongly modulates
miconazole anti-melanoma effect. In fact, in A375 cells, specific silencing by siRNA-KCNN2 leads to a
strong increase of miconazole anti-proliferative effect.
Interestingly, miconazole, while known as a relevant antifungal drug, is also known to recognizes
eukaryotic targets including several potassium channels. It has shown to induce cytoprotective
effect under hypoxia conditions, likely by inhibiting HMGB1 and IL-8 release in Caco-2 intestinal
cells [64]. Further, it has been shown to induce post-ischemic neurogenesis in rats [65], immune
response in fish [66], to have promising anti Alzheimer’s disease activity [67] and to interact with
the anticoagulant drug warfarin [68]. Further investigation on the underlying mechanism are
currently under investigation. In agreement with findings of the present study, other antifungal
compounds, namely itraconazole, show potent anti-melanoma action in vivo and in vitro on A-375
and SKMEL-28 cells, down-regulating different pathways including PI3K/mTOR [69]. Noteworthy,
increased melanogenesis is a frequent sing in fungal infections [70], fungal infections in some cases
mimicking melanoma lesions [71]. Accordingly, previous studies report anti-melanogenesis action
of antifungal compounds such as clotrimazole by interfering on ERK and PI3K/AKT activity [72].
Table 5 underlines that the known targets of miconazole are primarily involved in potassium transport,
arginine catabolism as well as guanylate cyclase activity and nitric oxide synthesis.
In conclusion all together these evidences support the role of ion channels in the melanoma
setup and future investigation on anti-melanoma effect in vivo of miconazole and other
anti-fungal compounds.
4. Materials and Methods
Ion channels investigated in the current study were taken from the list according to
HUGO Gene Nomenclature Committee (HGNC), European Bioinformatics Institute (EMBL-EBI) at
https://www.genenames.org/data/genegroup/#!/group/177. The ion channels list includes 328
genes and is reported in Table 1 in alphabetic order. The general procedure followed in the present
study is depicted in Figure 1. It consists of a preliminary in silico phase (screening phase, first-round
and second-round validation steps, and novelty assessment) and of a following experimental validation
of one of the identified molecular targets in proliferation/cell-death assays.
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In silico steps: screening phase and two validation steps. The screening and the two validation
steps were carried out onto a total of 170 patients (63 in the screening phase + 62 in the first round
validation + 45 in the third round validation).
Selection step: in silico selection of suitable melanoma markers. Expression of the 328 ion
channels genes reported in Table 1 was investigated in a collection of human melanoma biopsies
and controls. Namely, the melanoma GDS1375 dataset [73] (Talantov et al, 2005) from the GEO
database (https://www.ncbi.nlm.nih.gov/gds/) was chosen, containing expression data from 63
samples (45 melanoma-patients and 18 nevi-patients) with free data download. The significance of
the differential expression was evaluated according to Student t test analysis and fold change. ROC
analysis, the well accepted test for binary assessments [74], was then performed to measure how
effective is the expression-level of any given gene to discriminate healthy- from melanoma-biopsies.
The computed area under curve (AUC) value ranges from 0.5 to 1, indicating a minimum of 50% to a
maximum of 100% discrimination ability. Other datasets in the GEO database are available, such as
GDS1989 and GDS1965, but with only few samples. The GDS1375 dataset used in this selection step and
the GSE15605 dataset used in the following first validation step, were chosen due to the large number
of melanoma biopsies and control biopsies. Transcriptomic data are from Affymetrix Human Genome
U133A Array and from Affymetrix Human Genome U133 Plus 2.0 Array platforms, respectively.
In silico first validation step: validation of identified genes was carried out on a different GEO
dataset, namely GSE15605 [75] containing expression data form 62 patients-biopsies (namely 16
controls, 46 primary melanoma and 12 metastatic melanoma samples). The 20 genes showing
AUC > 0.90 computed according to the GDS1375 dataset, were analyzed in the GSE15605 dataset
and were considered validated if the computed AUC was >0.85. Under such condition, 11 genes
were validated.
In silico second validation step: a further validation of the genes passing the screening and the
first validation step was carried out in the Riker melanoma dataset [76] within the Oncomine database
(www.oncomine.org). Such dataset contains 45 human samples (40 metastatic melanoma samples and
five controls) and reports the expression values as log2-median centered intensity. This value was
used to calculate the ratio of melanoma vs. normal skin groups. A ratio higher than 2 or lower than
0.5 was considered effective to validate. Seven genes passed the second validation step. Five of these
seven genes (namely: SCNN1A, GJB3, KCNK7, GJB1, and KCNN2) show not-previously recognized
relation with melanoma, according to a PubMed search carried out in September 2018, highlighting
any co-occurrence of any gene-name and “melanoma” words in ALL fields. Therefore, these five genes
were considered novel in silico validated melanoma markers and potential therapeutic targets.
4.1. In Vitro Experimental Validation: Analysis of Potential “Druggability”
Drugs potentially targeting the in silico validated genes SCNN1A, GJB3, KCNK7, GJB1, and KCNN2
were then investigated on the database available at http://www.dgidb.org/search_interactions.
The analysis allows to identify FDA-approved drugs known to target the given genes.
4.2. Chilibot Analysis
Known functional interactions were investigated by Chilibot analysis (www.chilibot.net) [77].
Chilibot identifies literature–reported relationships within user-defined terms. This is achieved by
looking at their co-existence in the same sentence within Pubmed abstracts. Such procedure identifies
closer relations as compared to a plain Pubmed search. Chilibot then associates same-sentence
co-occurrence to stimulatory- or inhibitory- or non-interactive relationships. A pairwise search was
carried out indicating “melanoma”, “ion channels”, “miconazole” and “cytochrome P450” terms.
The “advanced options” button was turned on, to account for all known synonyms of the given terms
and minimize false negative findings (i.e., using all known synonyms in the search reduces the risk of
ignoring abstracts containing synonyms of the given term) and the analysis was performed on the
maximum number of abstracts possible (i.e., 50 abstracts).
Cancers 2019, 11, 446 17 of 22
4.3. Cell Culture and Melanoma Cells In Vitro Proliferation Assay
Cells were used from the 3rd to 5th passages. SKMEL-28 and A-375 melanoma cells were from
ATCC (Manassas, VA, USA) and were maintained in complete medium Dulbecco’s modified Eagle’s
medium (DMEM; Hyclone, South Logan, UT, USA) and in complete medium Minimum Essential
medium Eagle (MEM; Hyclone, South Logan, UT, USA) supplemented with 10% FBS (Hyclone), 2 mM
L-glutamine and 100 IU/mL penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) respectively
in humidified 5% CO2 atmosphere at 37 ◦C as described [78,79]. Human keratinocytes (HaCat) and
mouse embryonic fibroblasts (MEF cells) were from American Type Culture Collection (ATCC).
In some experiments, A-375 cells were treated with 3, 10, 30, and 50 µM of ammonium nitrate
(Merck, Darmstadt, Germany) as control of miconazole-nitrate, in 24 h proliferation assays.
The culture medium was changed every three days and when cells were sub-confluent; monolayers
were harvested by 1 min exposure to 0.1% Trypsin-EDTA (Life Technologies Inc, Carlsbad, CA, USA).
Miconazole nitrate was from CliniSciences (Paris, France). SKMEL-28 and A-375 cells were plated
at 10 × 105 and 8 × 104 respectively, in p35 plates dishes at time 0. Then cells were starved for 18 h in
serum-free medium and the next day treated with 3, 10, 30, and 50 µM of miconazole in complete fresh
medium containing 10% FCS and DMSO at a final concentration of 50 µM. Control cells were treated
with complete medium containing 10% FCS and DMSO at a final concentration of 50 µM. The effect of
miconazole nitrate on cells proliferation in vitro was measured by directly counting the number of
cells. At the end of incubation time (24, 48, and 72 h), cells were harvested and number of live cells
and dead cells was counted. Dead cells were quantified by trypan blue incorporation.
4.4. KCNN2 Silencing by siRNA
One day after plating (4 × 104 cells/mL), A-375 cells were transfected with Lipofectamine 2000
(Invitrogen) plus 50 nM small interfering RNA (siRNA) targeting KCNN2 gene (siRNA KCNN2)
(Santa Cruz, CA, USA) or with the corresponding non-specific control siRNA (siRNA non-specific)
(ThermoFisher, Waltham, MA, USA). After 5-h transfection, supernatant was discarded and fresh
complete medium was added. The next day, KCNN2 expression in transfected cells was measured
by Western blot analysis and miconazole treatment (10 µM) was started. After 24 h of miconazole
treatment, cell proliferation was measured.
4.5. Western Blot Analysis
Cells were washed with cold PBS and then cell lysates were prepared in cell lysis
buffer (Cell Signaling, Denvers, MA, USA), 1% sodium dodecylsulphate-polyacrylamide (SDS)
(Sigma-Aldrich, St Louis, MO, USA) and 1 mM phenylmethanesulfonyl fluoride solution (PMSF)
(Sigma-Aldrich, St Louis, MO, USA). Protein concentration was measured by a bicinchoninic acid
protein assay kit (Pierce, Rockford, IL, USA) according to manufacturer’s instructions and then
equal amounts of proteins (25 µg) were subjected to sodium dodecylsulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membrane (GE Healthcare, Life
science, Wien, Austria). Membranes were saturated with 5% non-fat dry milk in T-TBS, incubated with
the primary antibody overnight, and subsequently with horseradish peroxidase-conjugated (HRP)
secondary antibody for 1 h at room temperature. Membranes were washed with T-TBS and developed
using the chemiluminescence system (ECL Advance, Amersham Biosciences, San Diego, CA, USA).
Antibody used: anti KCNN2/SK2 antibody was from Abcam (San Francisco, CA, USA); anti-β-actin
was from Sigma (St Louis, MO, USA). Secondary antibody was HRP-goat anti-rabbit from Bio-Rad
(Hercules, CA, USA). The intensity of Western blot bands was quantified by Bio-RAD Chemidoc Gel
Imaging System with Image Lab 5.2.1. software (Bio-RAD, Hercules, CA, USA).
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4.6. STRING Analysis
STRING analysis at https://string-db.org/ was performed to identify the biological processes
most likely affected by the genes known to be miconazole targets. The “multiple proteins” search was
carried out.
4.7. Statistics
Statistical significance was computed according to the Student’s t-test; p < 0.05 was chosen as
significance threshold. ROC analysis was carried out with GraphPad Prism version 5 (GraphPad
Software, San Diego, CA, USA, www.graphpad.com).
The sensitivity and specificity values were computed as previously reported [51] as the values
corresponding to highest sensitivity-specificity product in each ROC curve data.
5. Conclusions
In conclusion, in the present study we show that many ion channels genes taken from the ion
channels families (i.e., 91 out of 328 investigated genes) are differently expressed in melanoma vs.
control human biopsies, according to an in silico analysis on 170 human samples. Five such genes
(namely: SCNN1A, GJB3, KCNK7, GJB1, KCNN2) were identified as potential strong melanoma markers
that had never been identified before. By in vitro experiments, one gene (namely: KCNN2) has been
validated as a relevant molecular target in melanoma cell lines. Indeed, the antifungal drug miconazole
shows an extremely high anti-proliferation activity in melanoma cell lines, mediated by KCNN2. We,
therefore, conclude that ion channels are strongly involved in melanoma and that miconazole may
exert a potent anti-melanoma activity.
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